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Introduction
1. INTRODUCTION
1.1. CHRONOPHARMACEUTICS AND CHRONOTHERAPY 1-3
The  goal  in  drug  delivery  research  is  to  develop  formulations  that  meet
therapeutic  needs  relating  to  particular  pathological  conditions.  Up to  late  1980`s
design of drug delivery systems governed by the homeostatic theory. This theory is
based on the assumption of biological  functions  that  display constancy over  time.
Research  in  chronopharmacological  field  has  demonstrated  the  importance  of
biological rhythms in drug therapy. Optimal clinical outcome cannot be achieved if
drug plasma concentrations  are constant.  If  symptoms of disease  display circadian
variations drug release should also vary over time. Formulations should be justified
by biopharmaceutical and pharmacokinetic study in order to choose the best hour for
administration. Another point raised by circadian variation of physiological function
is that drug pharmacokinetics can be time-dependent. Variations in physiological and
pathophysiological  functions  in  time,  also  need  for  variations  of  drug  plasma
concentration  has  brought  a  new  approach  to  the  development  of  drug  delivery
systems, chronopharmaceutical drug delivery.
The  human  body  has  many  built-in  rhythms  known  as  biological  clocks.
Broadly,  these  can  be  classified  as  Ultradian,  Circadian,  Infradian  and  Seasonal.
Ultradian cycles  are shorter  than a day,  e.g.  time taken for a nerve impulse to be
transmitted. Circadian cycles last about 24 hours, e.g. sleeping and waking patterns.
Infradian cycles are longer than a day, e.g. menstrual cycle. Recently, the role of these
rhythms in fighting disease and responding to medication has come under study by
researchers and scientists. The coordination of medical treatment and drug delivery
with such biological clocks and rhythms is termed Chronotherapy. 
In chronopharmacotherapy, drug administration is synchronized with circadian
rhythms. If the peak of symptoms occur at daytime a conventional dosage forms can
be administrated just before the symptoms are worsening. If symptoms of the disease
became  worse  during  the  night  or  in  the  early  morning  the  timing  of  drug
administration and nature of the drug delivery system need careful consideration. In
this case, modified-release dosage forms must be used. 
           To introduce the concept of chronopharmaceutics, it is important to define the
concepts  of  chronobiology  and  pharmaceutics.  Chronobiology  is  the  study  of
biological  rhythms  and  their  mechanisms.  Biological  rhythms  are  defined  by  a
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number of characteristics. The term “circadian” was coined by Franz Halberg from
the Latin circa, meaning about, and dies, meaning day. Oscillations of shorter duration
are termed ‘‘ultradian’’ (more than one cycle per 24 h). Oscillations that are longer
than 24 h are ‘‘infradian’’ (less than one cycle per 24 h) rhythms. Ultradian, circadian,
and infradian rhythms coexist at all levels of biologic organization.3
Chronobiological  studies  have  established  circadian  rhythm  for  almost  all
body functions. They are in synchrony with sleep - activity cycle of the individual.
The rhythms tend to fall into two groups. In the first are those that peak during the
daytime  and  are  associated  with  the  activity  phase  of  the  individual:  body
temperature, mental, physical and gastrointestinal activities, blood pressure, heart rate,
secretion of adrenaline etc. The second group, where rhythms show a peak during
nocturnal  sleep,  includes  secretion of  several  hormones,  among which  are  growth
hormone, cortisol and melatonin. Beside the physiological functions, the pathological
states  of  disease  have  also  circadian  rhythms.  Results  of  several  epidemiological
studies demonstrate the elevated risk of different pathology during 24-hour cycle.1
Pharmaceutics is an area of biomedical and pharmaceutical sciences that deals
with  the  design  and  evaluation  of  pharmaceutical  dosage  forms  (or  drug  delivery
systems)  to  assure  their  safety,  effectiveness,  quality and  reliability.  Traditionally,
drug delivery has meant getting a simple chemical absorbed predictably from the gut
or from the site of injection. A second-generation drug delivery goal has been the
perfection  of  continuous,  constant  rate  (zero-order)  delivery  of  bioactive  agents.
However, living organisms are not ‘‘zero-order’’ in their requirement or response to
drugs.  They  are  predictable  resonating  dynamic  systems,  which  require  different
amounts of drug at predictably different times within the circadian cycle in order to
maximize desired and minimize undesired drug effects.
Based  on  the  previous  definitions  “chronopharmaceutics  is  a  branch  of
pharmaceutics  devoted to the design and evaluation of  drug delivery systems
that release a bioactive agent at a rhythm that ideally  matches the biological
requirement of a given disease therapy”. 2
Ideally, chronopharmaceutical drug delivery systems (ChrDDS) should time-
controlled  and  site-specific  drug  delivery  systems.  Advantages  are  safer,  more
effective and reliable therapeutic effect taking into account advances in chronobiology
and chronopharmacology, system biology and nanomedicine. Evidence suggests that 
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an ideal ChrDDS should: (i) be non-toxic within approved limits of use, (ii) have a
realtime and specific triggering biomarker for a given disease state, (iii) have a feed-
back control system (e.g. self-regulated and adaptative capability to circadian rhythm
and  individual  patient  to  differentiate  between  awake–sleep  status),  (iv)  be
biocompatible and biodegradable, especially for parenteral administration, (v) be easy
to manufacture at economic cost, and (vi) be easy to administer in to patients in order
to enhance compliance to dosage regimen. Such ideal ChrDDS is not yet available on
the  market.  The  majority  of  these  features  may  be  found  at  the  interface  of
chronobiology, chronopharmacology, system biology and nanomedicine.
Figure1.1  Presents  the  overview  of  most  serious  diseases  displaying
significant  daily  variations.  Many  of  circadian  dependent  diseases  display  acute
symptoms in  early  morning hours  or  in the  morning at  awakening  . Most  asthma
attacks occur at 04:00 to 06:00 hours. Nocturnal asthma is a complex interaction of
several coincident circadian rhythms e.g. secretion of hydrocortisone and adrenalin.
Ischaemic hearth diseases, such as angina pectoris, myocardial infraction and stroke
manifests more frequently during the night or in the morning before breakfast. Rapid
increase in blood pressure is mostly responsible for these attacks. In hypertensive and
also in normotensive individuals the blood pressure arises notably before awakening.
Symptoms of rheumatoid arthritis and osteoarthritis have significant circadian rhythm.
Stiffness  and  pain  are  greatest  on  awakening  or  in  the  early  morning.  Circadian
rhythm of level of interleukin-6 is in good correlation with the rhythm of symptoms of
rheumatoid arthritis. Dyspnoea and peak of expiratory flow values have been found to
become worse during the night.
                                                 Fig.1.1: Disease Displaying Circadian Rhythm
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1.2 TIME-CONTROLLED RELEASE DOSAGE FORMS 4-5 
Oral  drug  delivery  is  the  most  popular  and  convenient  form  of  the  drug
administration.  Evolution  of  oral  solid  dosage  forms  on  the  basis  of  dissolution
profile:
• From 1950-s. conventional (immediate release) dosage forms
• From 1960-s. prolonged-release (sustained-release) dosage forms
•  From  late  1980-s.  pulsatile  or  prolonged-release  dosage  forms  following  a  lag
period.
Modified-release formulations have many advantages over immediate-release
formulations. With these formulations a less frequent drug administration is possible,
lower  peak  concentrations  can  be  obtained  to  avoid  adverse  effects  and  patient
compliance can be improved. The modified-release dosage forms can be divided into
subgroups of rate-controlled-release, delayed-release and pulsed-release formulations.
Delayed-release formulations include time-controlled release and site-specific dosage
forms.  Time-delayed  delivery  system  (time-controlled  release  formulations  and
pulsed release formulations) is the best approach to deliver drugs in accordance with
circadian rhythms of the disease. The mentioned approach serves a purpose especially
in  the  treatment  of  early  morning  symptoms.  By  timing  the  drug  administration,
plasma peak is obtained at an optimal time. Number of doses per day can be reduced.
When there are no symptoms, there is no need for drugs. First pass metabolism and
tolerance development can also be avoided. 
   The  influence  on  chronokinetic  of  the  route  of  administration  must  also  be
considered.  For  example,  there  are  studies  showing  that  chronopharmacokinetic
variation is not found when drug is administrated rectally. Circadian variation in the
activity of many gastrointestinal, hepatic and renal processes could explain why the
absorption, distribution, metabolism and excretion of drugs change as a function of
the time of administration. The drug absorption process can be altered by factors as
the structure of membrane, the physicochemical properties of drugs, the pH, the rate
of gastric emptying and the motility the blood flow to the gastrointestinal tract. No
study is available presently on temporal variations in the structure of membranes or
on the effect of circadian changes of pH on drug absorption.
1.3 CHRONOPHARMACEUTICAL DRUG DELIVERY SYSTEM 2
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Controlled drug delivery systems have acquired a center stage in the arena of
pharmaceutical  R&D business.  Such systems offer  temporal  and/or  spatial  control
over the release of drug and grant a new lease of life to a drug molecule in terms of
patentability.  These  dosage  forms  offer  many advantages,  such as  nearly  constant
drug level at the site of action, prevention of peak-valley fluctuations, reduction in
dose  of  drug,  reduced  dosage  frequency,  avoidance  of  side  effects,  and improved
patient compliance. The oral controlled-release system shows a typical pattern of drug
release in which the drug concentration is maintained in the therapeutic window for a
prolonged period of time (sustained release), thereby ensuring sustained therapeutic
action. Thus, the release commences as soon as the dosage form is administered as in
the case of conventional dosage forms.
There  are  certain  conditions  for  which  continuous  conventional  controlled
release pattern is not suitable. These conditions demand release of drug after a lag
time.  Therefore  require  a  pulsatile  delivery.  A  pulsatile  drug  delivery  system  is
characterized by a lag time that is an interval of no drug release followed by rapid
drug release. The first pulsed delivery formulation that released the active substance
at a precisely defined time point was developed in the early 1990s. In this context, the
aim of  the  research  was  to  achieve  a  so-called  sigmoidal  release  pattern.  The
characteristic feature of the formulation was a defined lag time followed by a drug
pulse with the enclosed active quantity being released at once.
Fig.1.2: Drug Release Profile of Pulsatile Drug Delivery System
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Thus,  the  major  challenge  in  the  development  of  pulsatile  drug  delivery
system is to achieve a rapid drug release after the lag time. Often, the drug is released
over an extended period of time. 
1.3.1 Currently reported systems 3-7
Pulsatile systems are basically time-controlled drug delivery systems in which
the  system  controls  the  lag  time  independent  of  environmental  factors  like  pH,
enzymes,  gastro-intestinal  motility,  etc.  These  time-controlled  systems  can  be
classified as single unit (e.g., tablet or capsule) or multiple unit (e.g., pellets) systems.
1.3.1.1 Single unit system
1.3.1.1.1. Capsular systems
Different  single-unit  capsular  pulsatile  drug  delivery  systems  have  been
developed. A general architecture of such systems consists of an insoluble capsule
body housing a drug and a plug. The plug is removed after a predetermined lag time
owing to swelling, erosion or dissolution.
1.3.1.1.2. Pulsincap systems 
The Pulsincap system is made up of a water-insoluble capsule body filled with
drug formulation. The body is closed at the open end with a swellable hydrogel plug.
Upon contact  with  dissolution medium or gastro-intestinal  fluids,  the plug swells,
pushing itself out of the capsule after a lag time. This is followed by a rapid drug
release. Manipulating the dimension and the position of the plug can control the lag
time. 
Fig. 1.3: Pulsatile release from an insoluble capsule body (Coated swellable plug; and Erodible
plug Capsular System Based on Osmosis)
The plug material consists of insoluble but permeable and swellable polymers
(eg,  polymethacrylates),  erodible  compressed  polymers  (eg,  hydroxypropylmethyl
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cellulose,  polyvinyl  alcohol,  polyethylene  oxide),  congealed  melted  polymers  (eg,
saturated  polyglycolated  glycerides,  glyceryl  monooleate),  and  enzymatically
controlled erodible polymer (e.g. pectin). These formulations were well tolerated in
animals  and  healthy  volunteers,  and  there  were  no  reports  of  gastro-intestinal
irritation. However, there was a potential problem of variable gastric residence time,
which was overcome by enteric coating the system to allow its dissolution only in the
higher pH region of small intestine.
1.3.1.1.3. Port systems 
The  Port System  consists  of  a  gelatin  capsule  coated  with  a  semi
permeable membrane (eg,  cellulose acetate,  PLGA) housing an insoluble plug
(eg, lipidic) and an osmotically active agents (NaHCo3, Citric acid) along with the
drug formulation (Fig.1.5.).When in contact  with the aqueous medium, water
diffuses  across  the  semi  permeable  membrane,  resulting  in  increased  inner
pressure that ejects the plug after a lag time. Coating thickness controls the lag
time. The system was proposed to deliver methylphenidate for the treatment of
attention deficit hyperactivity disorder (ADHD) in school-age children. Such a
system avoids a second daily dose that otherwise would have been administered
by a nurse during school hours.
                        Fig.1.4: Drug Release Mechanism from PORT System.
1.3.1.1.4. A System based on expandable orifice 2-3
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To deliver the drug in liquid form, an osmotically driven capsular system was
developed in which the liquid drug is absorbed into highly porous particles, which
release  the drug through  an orifice  of  a  semi permeable  capsule  supported  by an
expanding  osmotic  layer  after  the  barrier  layer  is  dissolved.  The  capsular  system
delivers  drug  by  the  capsule’s  osmotic  infusion  of  moisture  from the  body.  The
capsule wall is made up of an elastic material and possesses an orifice. As the osmosis
proceeds, the pressure within the capsule rises, causing the wall to stretch. The orifice
is small enough so that when the elastic wall relaxes, the flow of the drug through the
orifice  essentially  stops,  but  when  the  elastic  wall  is  distended  beyond  threshold
value,  the  orifice  expands  sufficiently  to  allow  drug  release  at  a  required  rate.
Elastomers,  such  as  styrene-butadiene  copolymer  have  been  suggested.  Pulsatile
release was achieved after lag times of 1 to 10 hours, depending on the thickness of
the barrier layer  and that of semipermeable membrane, and a capsule designed for
implantation can deliver drug intermittently at intervals of 6 hours for 2 days.
1.3.1.1.5. Delivery by a series of stops 2
The implantable capsules containing a drug and a water-absorptive osmotic
engine are placed in compartments separated by a movable partition. The pulsatile
delivery is achieved by a series of stops along the inner wall of the capsule. These
stops obstruct the movement of the partition but are overcome in succession as the
osmotic  pressure  rises  above  a  threshold  level.  The  number  of  stops  and  the
longitudinal  placements  of  the  stops  along  the  length  of  the  capsule  dictate  the
number and frequency of the pulses, and the configuration of the partition controls the
pulse intensity. This system was used to deliver porcine somatotropin.
1.3.1.1.6. Pulsatile delivery by solubility modulation 
The system was especially developed for delivery of salbutamol sulphate. The
compositions contain the drug (salbutamol sulphate) and a modulating agent (sodium
chloride, NaCl). The modulating agent can be a solid organic acid, inorganic salt, or
organic  salt.  In  order  to  control  zero-order  release  period  and  commencement  of
pulsed release, ratio of drug/modulator can be varied. After the period of zero-order
release, the drug is delivered as one large pulse.
1.3.1.1.7. Pulsatile systems with erodible or soluble barrier coating. 8
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Most of the pulsatile drug delivery systems are reservoir devices coated with a
barrier layer. This barrier erodes or dissolves after a specific lag period, and the drug
is subsequently released rapidly. The lag time depends on the thickness of the coating
layer.
1.3.1.1.8. Time clock systems 2
The Time Clock system consists of a solid dosage form coated with lipidic
barriers  containing  carnuba  wax  and  bees’  wax  along  with  surfactants,  such  as
polyoxyethylene sorbitan monooleate.  This coat erodes or emulsifies in the aqueous
environment in a time proportional to the thickness of the film, and the core is then
available for dispersion. Such systems are better suited for water-soluble drugs. The
major  advantage  of  this  system is  its  ease  of  manufacturing  without  any need  of
special  equipment.  However,  such  lipid-based  systems  may  have  high  in-vivo
variability (eg, food effects).
1.3.1.1.9. Chronotropic systems 2
The  Chronotropic system  consists  of  a  drug-containing  core  coated  by
hydrophilic swellable hydroxypropylmethyl cellulose (HPMC), which is responsible
for a lag phase in the onset of release. In addition, through the application of an outer
gastric-resistant enteric film, the variability in gastric emptying time can be overcome,
and a colon-specific release can be obtained, relying on the relative reproducibility of
small  intestinal  transit  time.  The  lag  time  is  controlled  by  the  thickness  and  the
viscosity grades of HPMC.
1.3.1.1.10. Multilayered tablet 
A release pattern with two pulses was obtained from a three-layered tablet
containing two drug containing layers  separated by a drug-free gellable polymeric
barrier layer. This three-layered tablet was coated on three sides with in impermeable
ethyl cellulose, and the top portion was left uncoated. Upon contact with dissolution
medium, the initial dose incorporated into the top layer was released rapidly from the
non-coated surface. The second pulse was obtained from the bottom layer after the
gelling barrier layer of HPMC was eroded and dissolved. The rate of gelling and/or
dissolution of the barrier layer control the appearance of the second pulse. The gelling
polymers  reported  include  cellulose  derivatives  like  HPMC,  methyl  cellulose,  or
polyvinyl  alcohols of various  molecular  weights  and the coating materials  include
ethyl  cellulose,  cellulose-acetate-propionate,  methacrylic  polymers,  acrylic  and
mehtacrylic co-polymers, and polyalcohols.
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1.3.1.1.11. Pulsatile systems with rupturable coating 8 
The effervescent excipients, swelling agents, or osmotic pressure can achieve
the pressure necessary for the rupture of the coating. An effervescent mixture of citric
acid  and  sodium bicarbonate  was  incorporated  in  a  tablet  core  coated  with  ethyl
cellulose.  The  carbon  dioxide  developed  after  penetration  of  water  into  the  core
resulted in a pulsatile release of drug after rupture of the coating. The release may
depend on the mechanical properties of the coating layer. The highly swellable agents,
also called superdisintegrants, are used to design a capsule-based system comprising a
drug, swelling agent, and rupturable polymer layer.  The lag time is function of the
composition of the outer polymer layer.  The presence of hydrophilic polymer like
HPMC reduces the lag time. The system can be used for delivery of both solid and
liquid  drug  formulations.  A  reservoir  system  with  a  semipermeable  coating  was
designed  for  delivery  of  drugs  that  exhibit  extensive  first-pass  metabolism.  The
release pattern was similar to that obtained after administration of several immediate-
release doses.
1.3.1.2. Multiparticulate systems
Multiparticulate  systems  (e.g.,  pellets)  offer  various  advantages  over  single
unit systems. These include no risk of dose dumping, flexibility of blending units with
different release patterns, and reproducible and short gastric residence time. But the
drug-carrying capacity of multiparticulate systems is lower due to presence of higher
quantity  of  excipients.  Such  systems  are  invariably  a  reservoir  type  with  either
rupturable or altered permeability coating.
1.3.1.2.1. Pulsatile system based on rupturable coating 8
Time controlled explosion system: This is a multiparticulate system in which
drug  is  coated  on  non  pareil  sugar  seeds followed  by  a  swellable  layer  and  an
insoluble top layer. The swelling agents used include superdisintegrants like sodium
carboxymethyl cellulose, sodium starch glycollate, hydroxypropyl cellulose, polymers
like polyvinyl  acetate,  polyacrylic acid,  polyethylene  glycol,  etc.  Alternatively,  an
effervescent system comprising a mixture of tartaric acid and sodium bicarbonate may
also be used. Upon ingress of water, the swellable layer expands, resulting in rupture
of  film  with  subsequent  rapid drug  release.  The  release  is  independent  of
environmental  factors  like pH and drug solubility.  The lag time can be varied  by
varying  coating  thickness  or  adding  high amounts  of  lipophilic  plasticizer  in  the
outermost  layer.  A rapid  release  after  the  lag phase  was  achieved  with  increased
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concentration of osmotic agent.  Invivo  studies of time-controlled explosion system
(TCES) with an invitro  lag time of three hours showed appearance of drug in blood
after 3 hours, and maximum blood levels after 5 hours.
1.3.1.2.2. Osmotic based rupturable coating systems 3,9-10
Permeability controlled system:  This system is based on a combination of
osmotic and swelling effects. The core containing the drug, a low bulk density solid
and/or liquid lipid material  (eg,  mineral  oil) and a disintegrant was prepared. This
core was then coated with cellulose acetate.  Upon immersion in aqueous medium,
water  penetrates  the  core  displacing  lipid  material.  After  the  depletion  of  lipid
material, internal pressure increases until a critical stress is reached, which results in
rupture of coating.
The  use  of  osmotically  active  agents  that  do  not  undergo  swelling  was
reported by Schultz and Kleinebudde. The pellet cores consisted of drug and sodium
chloride.  These were coated with a semipermeable cellulose acetate  polymer.  This
polymer is selectively permeable to water and is impermeable to the drug. The lag
time increased with increase in the coating thickness and with higher amounts of talc
or lipophilic plasticizer in the coating. The sodium chloride facilitated the desired fast
release of drug. In absence of sodium chloride, a sustained release was obtained after
the lag time due to a lower degree of core swelling that resulted in generation of small
fissures.
Chen has also proposed a system containing a core of drug and osmotically
active agent (sodium chloride) coated with an insoluble permeable membrane. The
coating  materials  reported  include  different  types  of  poly  (acrylate-methacrylate)
copolymers  and  magnesium  stearate,  which  reduces  water  permeability  of  the
membrane, thus allowing for use of thinner films. Thicker films are to be avoided as
they do not rupture completely.  Using ethyl cellulose as a coating material, it  was
possible  to  affect  lag  time  of  enteric  polymer  to  achieve  rupturing  after  a
predetermined time.
1.3.1.2.3. Pulsatile delivery by change in membrane permeability 2-3 
The  permeability  and  water  uptake  of  acrylic  polymers  with  quaternary
ammonium groups can be influenced by the presence of different counter ions in the
 medium. Several delivery systems based on this ion exchange have been developed.
Eudragit RS 30D is reported to be a polymer of choice for this purpose. It typically
contains positively polarized quaternary ammonium group in the polymer side chain,
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which  is  always  accompanied  by  negative  hydrochloride  counter  ions.  The
ammonium group being hydrophilic facilitates the interaction of polymer with water,
thereby changing its permeability and allowing water to permeate the active core in a
controlled manner. This property is essential to achieve a precisely defined lag time.
The cores were prepared using theophylline as model drug and sodium acetate. These
pellets were coated using Eudragit RS30D (10% to 40% weight gain) in four different
layer thicknesses. A correlation between film thickness and lag time was observed.
After  the  lag  time,  interaction  between  the  acetate  and  polymer  increases  the
permeability of  the coating so significantly that  the entire  active dose is  liberated
within a few minutes. The lag time increases with increasing thickness of the coat, but
the release of the drug was found to be independent of this thickness and depended on
the amount of salt present in the system.
1.3.1.2.4. Sigmoidal release systems 4
This consists of pellet cores comprising drug and succinic acid coated with
ammonio methacrylate copolymer USP/NF type B. The lag time is controlled by the
rate of water  influx through the polymer membrane.  The water  mix with succinic
acid, and the drug in the core and the acid solution in turn increases permeability of
the hydrated  polymer  film.  In  addition to succinic acid,  acetic  acid,  glutaric  acid,
tartaric acid, malic acid, or citric acid can be used. The increased permeability can be
explained by improved hydration of film, which increases free volume.34, 35      
1.3.1.3. Other systems
1.3.1.3.1. Enzyme containing capsular shaped pulsatile drug delivery systems
Krogel I.  et al (1999) developed and evaluated an alternative pulsatile drug
delivery system consisting of a drug containing, impermeable capsule body closed
with an enzyme degradable plug. The degradation of plug material was not controlled
by enzymes being present in the GIT, but by an enzyme being directly incorporated in
the plug. The enzyme degradable plug consisted of the natural polysaccharide pectin,
which is widely used in the food industry as a thickening agent and a pectinolytic
enzyme mix. In this system pulsatile drug release is enzymatically controlled which is
based on an impermeable capsule body which contains the drug and is closed by an
erodible pectin / pectinase plug.
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Fig.1.5: Schematic diagram of a one layer pulsatile DDS with an impermeable
capsule body and pulsatile DDS with a two layer plug.
The powder (pectin and pectinolytic enzyme in different ratios) was blended
and  plug  was  prepared  by  direct  compression  with  single  punch  press.  The
compressed  plug  was  placed  manually  within  the  orifice  of  the  drug  filled  poly
(propylene) capsule body, with the top of the capsule body and the plug being even.
The enzyme free layer of the two layers, plug was on the top of the capsule. The plug
that  consist  of  a  mixture  of  enzyme degradable  polymer  and the enzyme,  acts  as
release barrier. The polymer is degraded by enzyme after aqueous contact. Ideally no
drug is released until the complete plug is degraded, leading to a defined lag time
prior to the drug release. The two layer plug was prepared to separate the polymeric
substance  from  the  enzyme  and  to  protect  enzyme  from  the  possibly  degrading
enzyme in GIT fluid. However, the lag time prior to drug release from the two layer
DDS was longer then 6 hour and the subsequent drug release occurs in the sustained
not in the pulsatile manner because the plug material  was not completely emptied
from the orifice. Hence one layered system is more important for study.
1.3.1.3.2. Modified pulsincap technique 
Murthy et al (2001) developed modified pulsincap preparation for rifampicin
release studies of various hydrophilic polymers,  such as Guar gum, Carbopol 940,
Sodium  alginate,  HPMC,  Methyl  cellulose,  Gum  karaya  and  poly  vinyl  alcohol.
Increase in the hydrophilic polymer content results in reduction in the release rate of
the drug. Pulsincap was a patented preparation, consisting of hardened capsule body
filled  with  basic  drug  mixture  and  sealed  with  hydrogel  plug.  After  embedding
sufficient amount of water the hydrogel plug will be released at predetermined time
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and the total content of the capsule will be released into the GIT fluids. Hence this
preparation is regarded as time release dosages form. In modified pulsincap, the drug
polymer  mixture is  filled into the capsule body.  The release  rate  of  the drug was
controlled by the formation of the viscous hydrogel  within the capsule body.  This
technique controls the drug release rate whereas pulsincap preparation controls the
drug release time.
1.3.1.3.3. Configuration of tablet matrix in impermeable cylinder
A  multifunctional  drug  delivery  system  based  on  HPMC  matrices  placed
within  an  impermeable  polymeric  cylinder  (open  at  both  ends)  was  developed.
Depending on the configuration of the device, extended release, floating or pulsatile
drug delivery system could be obtained. This system can be of three types:
Fig.1.6: Configuration of multifunctional matrix delivery system.
1. One drug containing tablet within an impermeable cylinder.
2. Floating device (one tablet at each end of the cylinder with an air filled space in the
middle).
3. Pulsatile system (drug filled impermeable capsule half closed with an erodible drug
free plug).
The release behavior of the different devices was investigated as a function of
HPMC viscosity grade, HPMC content, type of drug, matrix weight, and position of
the matrix within the polymer cylinder, addition of various fillers and agitation rate of
the  release  medium.  Drug  release  increases  with  reduce  HPMC  viscosity  grade,
higher aqueous drug solubility, decrease HPMC content and increase surface area of
the matrix. The release was fairly independent on the agitation rate, the position of the
tablet  within the polymeric cylinder  and length of the cylinder.  With the pulsatile
device, the lag time prior to drug release could be controlled through the erosion rate
of the matrix.
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1.3.1.3.4. Stimuli induced pulsatile release 4-5 
1.3.1.3.4.1. Thermo responsive hydrogel systems
In  closed  loop  systems,  or  self  regulated  systems,  the  release  is  in  direct
response  to  the  conditions  detected  the  temperature,  type  of  solvent,  pH,  or
concentration. Poly (N-isopropylacrylamide) (PIPAAM) is a well known example of
a thermo responsive polymer.  At  its  transition of  32ºC,  the polymer  is  soluble in
water; but, as temperature is increased, the polymer precipitates and phase separates.
Poly (ethylene glycol) and poly (propylene glycol) copolymers and poly (lactic acid)
and  poly  (glycolic  acid)  copolymers  also  exhibit  thermo  responsiveness.  These
polymers  are  useful  in  developing  thermo  gelling  systems  (Atridox);  the  drug  is
dissolved in the liquid form of the polymer at room temperature. When this mixture is
injected in the body,  the polymer turns into a gel,  which eventually degrades  and
releases the drug molecules. Drug release from the PIPAAM hydrogel at temperature
below 32°C was governed by diffusion, while above this drug release was stopped
completely due to skin layer  formation on the  gel  surface.  Akihiko Kikuchi  et  al
(2004) have recently reported a new method to accelerate gel swelling / deswelling
kinetics based on molecular design of the gel structure. Free mobile linear PIPAAM
chains were grafted within the crossed linked PIPAAM hydrogels. The drug release
profile from the graft type PIPAAM gels were monitored after the immersion of the
drug containing gels  in a  suitable release  medium. Low molecular  weight  sodium
salicylate  was released in one burst  from conventional  PIPAAM gels immediately
after a temperature increased, after which the release terminated due to formation of a
dense impermeable skin layer on the surface.
1.3.1.3.4.2. Thermoresponsive polymeric micelle systems
Kataoka et al (2001) comprehensively reviewed the properties and biological
response of polymeric micelles making them the most noteworthy candidate as drug
carrier for the treatment of cancer. The polymeric micelle is composed of amphiphilic
block copolymers exhibiting a hydrophobic core with a hydrophilic corona. Due to
this unique structure characteristic, polymer micelle exhibits characteristics that are
not detected by the reticuloendothelial system (RES). Thus the passive targeting could
be  achieved  through  a  enhanced  permeation  retention  effect  of  the  tumor  sites.
Blockco polymers  formed micellar structure (with core shell structure)  in aqueous
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solution   below Tg temperature. The micelle formation was confirmed by dynamic
light scattering measurements.
1.3.1.3.5. Chemical stimuli induced pulsatile release
1.3.1.3.5.1. Glucose responsive insulin release devices  
Self regulating insulin delivery devices depend on the concentration of glucose
in the blood to control the release of insulin. Ishihara et al (1983) prepared one gel
membrane  system  to  regulate  the  insulin  permeability.  The  system  proposed
immobilizing glucose oxidase (an enzyme) to a pH responsive polymeric hydrogel,
which  encloses  a  saturated  insulin  solution.  At  high  glucose  levels,  glucose  is
catalyzed by glucose oxidase and converts it to gluconic acid, thus lowering the pH.
This decrease in pH causes  the membrane to swell,  forcing the insulin out of the
device.
1.3.1.3.5.2. Inflammation induced pulsatile release 
During  inflammation,  hydroxyl  radicals  (-OH)  are  produced  from  the
inflammation responsive cells. Yui et al (1993) focused on the inflammatory induced
hydroxyl radicals and designed drug delivery system, which responded to hydroxyl
radicals  and  degraded  in  a  limited  manner.  In  the  body hyaluronic  acid  (HA)  is
degraded either by specific enzyme, hyaluronidase, or hydroxyl radicals. Thus they
prepared  crossed  linked  HA  with  ethylene  glycol  di-glyceride  ether.  When
microspheres  were  incorporated  in  the  HA  hydrogel  as  a  model  drug,  these
microspheres were released only when hydroxyl radicals induced HA gel degradation.
Control HA gel implanted in the animals were relatively stable over a period of 100
days.  Thus  it  is  possible  to  treat  patients  with  inflammatory  disease,  such  as
rheumatoid arthritis,  using anti-inflammatory drug incorporated  HA gels  as a new
implantable drug delivery system.
1.3.1.3.5.3.  Drug  release  from  intelligent  gels  responding  to  antibody
concentrations 
There are numerous types of bioactive compounds, which exist in the body.
Recently, novel gels were developed which responded to the change in concentration
of bioactive compounds to alter their swelling/ deswelling characteristics. Miyata et al
(1999) focused on the introduction of stimuli responsive cross-linking structure into
hydrogels. A special attention was given to antigen antibody complex formation as
the cross linking unit in the gel, because specific antigen recognition of an antibody
can  provide  the  basis  for  a  new  device  fabrication.  Utilizing  the  difference  in
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association  constants  between  polymerized  antibodies  and  naturally  derived
antibodies  toward  specific  antigens,  reversible  gels  swelling/  deswelling  and  drug
permeation changes occurred. Thus the biological stimuli responsive hydrogels were
created.
1.4 FLOATING PULSATILE DRUG DELIVERY SYSTEM 11
    There are numerous approaches to prolong gastric retention, floating drug delivery
system is the most widely used technique and offers a simple practical approach to
increased gastric residency through inherent buoyancy.  Floating has been achieved
with  the  preparation  of  low density  dry solid  systems  (e.g.  inclusion  of  sponges,
highly porous systems) or with systems, which decrease in density upon contact with
gastric fluids based on the expansion of swelling agents or CO2 generation. Pulsatile
drug delivery systems are characterized by two release phases, a first phase with no or
little  drug  being  released,  followed  by a  second phase,  during which  the  drug  is
released completely within a short period of time after the lag time. The release can be
either  time  or  site  controlled.  The  release  from  the  first  group  is  essentially
determined  by  the  system,  while  the  release  from the  second  group  is  primarily
controlled by the biological environment in the gastrointestinal tract Most pulsatile
delivery systems are reservoir devices covered with a barrier coating, which dissolves
erodes or ruptures after a certain time period, followed by rapid drug release from the
reservoir. Reservoir type delivery systems based on the expansion of the core have
been  evaluated  for  both  floating  delivery  systems  having  a  lower  density  than
gastrointestinal fluids, and for pulsatile systems in which the core expansion causes
rupturing of the coating to allow rapid drug release.
     The system consists of three different parts, a core tablet, containing the active
ingredient, an erodible outer shell, and a top cover buoyant layer (Fig. 6.2). One layer
is for buoyancy and the other for drug pulsatile release. The pulsatile release system
with various lag times was prepared by compression with different erodible polymeric
layers (press-coated systems) as described previously. Ideally, the novel system could
result in (1) a floating dosage form with a prolonged gastric residence time and in (2)
a pulsatile dosage form, in which the drug is released rapidly in a time controlled
fashion after rupturing of the coating.                   
RVS College of Pharmaceutical Sciences, Coimbatore  17
Introduction
Figure 1.7.  Schematic diagram of the floating–pulsatile release (FPRT) delivery
system. 
 A: the layer for buoyancy; B: the layer for drug pulsatile release; C: the rapid-
release core tablet.
1.5  PRESS  COATING  TECHNIQUE  (COMPRESSION  COATED
TECHNIQUE) 2,12
The  addition  of  an  IR  component  allows  one  to  design  delivery  systems  having
optimal  pharmacokinetic  profiles  and  enables  the  combination  of  different  drugs
thereby improving patient compliance. To achieve this combination IR plus osmotic
CR dosage form, bilayer systems may be prepared by spray coating a coated core CR
tablet with a solution containing the IR drug either as part of the drug  delivery rate
controlling coating or on the outside of that coating. In spray coating the drug, it must
either be dissolved or dispersed in the coating fluid. In many cases, dissolution of the
drug results in stability issues, either because the drug itself is unstable in solution, or
because in the spraying and drying process, the drug precipitates from solution in a
less stable morphology (such as amorphous). For low solubility drugs, dissolution in
an  appropriate  solvent  may require  high  dilution with resulting prohibitively long
coating run times. Although drug dispersions can be prepared and coated, many drugs
present difficult challenges For example, the drug must be insoluble in the coating
solvent. The drug must also be kept in suspension during the spray coating process.
Content uniformity (tablet to tablet) tablet can be especially challenging if there is
settling or agglomeration. The press coating technique offers advantages over liquid
coating  as  it  does  not  involve  the  use  of  solvents,  requires  a  relatively  short
manufacturing process, and allows greater weight gain to the core tablet. However,
common  drawbacks  of  the  press  coating  technique  are  the  multi-step  processes
involved, and the requirement for reliable and reproducible central positioning of the
core tablet within press coated tablet (PCT).    
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Fig.1.8:  Press coating technique
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1. Nifedipine is widely used for its anti-hypertension and anti-anginal properties. So
nifedipine is a typical example of drug, which is used in the therapy of symptoms or
diseases as described28-29.
2. However, for such cases, conventional drug delivery systems are inappropriate for
the delivery of Nifedipine, as they cannot be administered just before the symptoms
anti-hypertension and anti-angina,because during this time the patients are asleep.1-2
3.Dossage form and dose 27-29 
   Dossage form: Immediate release tablet and sustained release tablet
   Dose: 20 mg
4. Advantages of pulsatie drug delievery systems are as follow 2
a) Extended daytime or nighttime activity
b) Reduced side effects
c)  Reduced dosage frequency
d) Reduction in dose size
e) Improved patient compliance
f) Drug adapts to suit circadian rhythms of body functions or diseases.
g) Drug targeting to specific site like colon.
h) Protection of mucosa from irritating drugs.
i) Drug loss is prevented by extensive first pass metabolism.
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                              2. LITERATURE REVIEW
Huda et al. (2012)  13 formulated sustained release matrix tablets of a poorly water
soluble  drug  nifedipine  using   hydrophilic  polymers  Methocel  K15M  CR  and
Methocel K100LV CR by direct compression method. The tablets were subjected to
various tests for their physical parameters such as thickness, hardness and friability
and  in  vitro  release  study  was  carried  out  for  12  hours  using  USP  paddle  type
dissolution  apparatus  in  phosphate  buffer  with  sodium  lauryl  sulphate  (pH  6.8).
Quantitative evaluation by mathematical model indicates that formulation containing
HPMC K15M CR and HPMC K100LV CR in a ratio of 1:3 showed better dissolution
properties compared to other ratio.  The study indicates that the hydrophilic matrix
tablets of nifedipine prepared using Methocel K15M CR and Methocel K100LV CR
can successfully be employed as twice a day oral controlled release dosage form in
order to improve patient compliance.
 Ghosh S et al (2010) 14  developed a sustained release matrix tablet formulation of
water soluble Nifedipine hydrochloride using multi unit chitosan treated alginate. The
addition of chitosan increased the swelling of multiple unit systems (MUS) in acidic
conditions and reduced the drug release from MUS. The sustained release formulation
of  nifedipine  is  absorbed  uniformly  from  the  entire  gastro  intestinal  tract.  It  is
administrated orally in  relatively small  dose  of  20 mg.  This  study shows that  the
matrix type chitosan treated alginate MUS can be used to formulate sustained release
tablets to deliver nifedipine hydrochloride for more than 12 hours
Gosai  A  et  al.  (2008)15  formulated  orodispersible  tablets  of  ondansetron
hydrochloride. Because of its application in emesis condition, fast onset of action is
desirable. Tablets were prepared by direct compression using sodium starch glycolate
and  croscarmellose  as  superdisintegrants,  as  the  combination  of  these  two
superdisintegrants gives better disintegration of the tablet. The tablets were evaluated
for  weight  variation,  mechanical  strength,  in  vitro  disintegration  time,  in  vivo
disintegration  time,  wetting  time,  and  drug  release  characteristics.  Hardness  and
friability  data  indicated  mechanical  strength  of  tablets.  The  results  of  in  vitro
disintegration time and in vivo disintegration time indicated that the tablets dispersed
rapidly in mouth within 3 to 5 seconds. Dissolution study revealed faster release rate 
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of ondansetron hydrochloride as compared marketed conventional tablet formulation
of  ondansetron  hydrochloride.  It  was  concluded  that  superdisintegrants  addition
technique  is  a  useful  method  for  preparing  orodispersible  tablets  by  direct
compression method.
Rajendran N  et  al.  (2011)16 formulated  immediate  release  tablets  of  olopatadine
hydrochloride to study the effect of superdisintegrants and processing methods on the
physicochemical  and  in-vitro  release  characteristics.  Various  formulations  of
olopatadine were prepared by direct compression, wet granulation and fluidized bed
granulation methods to achieve maximum drug content with reference to innovator.
Varying proportion of superdisintegrants such as crosspovidone XL, sodium starch
glycolate, croscarmellose sodium used to compare drug release profile with innovator.
Formulations  were prepared  and evaluated  with respect  to various precompression
and postcompression parameters. The results indicate that the superdisintegrants used
such  as  crosspovidone  XL,  sodium  starch  glycolate,  croscarmellose  sodium have
influence on the disintegration time.
Deshmukh G  et  al (2011)  17 developed fast  disintegrating tablets  of  Lamotrigine
using  Micro  crystalline  cellulose  and  Lactose  Monohydrate  IP  as  diluents  and
Aspartame  as  sweetening  agent  along  with  three  different  levels  of  two  super
disintegrants sodium starch glycolate and kyron T-314. Tablets were evaluated for
weight variation, hardness, friability, thickness, wetting time, and disintegration time
(DT)  and  dissolution  study. The  results  of  above  experiments  revealed  that  the
concentration of super disintegrating agents, sodium starch glycolate and Kyron T 314
significantly affect the disintegration time of prepared tablets.
Metker V  et al (2011)18  developed mouth dissolving tablets of lornoxicam by wet
granulation  technique  using  kyron  T-314  as  superdisintegrant  and  menthol  as
subliming agent. Polacrillin Potassium (kyron T-314) is a cation exchange resin used
in  oral  pharmaceutical  formulation.  From  the  study,  it  can  be  concluded  that
formulations  prepared  by  sublimation  technique  gives  better  release  profile  and
increase absorption of the drug. Formulations with kyron T-314 as superdisintegrant 
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disintegrates  within  few  seconds  without  need  of  water  and  enhance  absorption
leading to its increased bioavailability.
Bhat A  et  al.  (2011)  19 developed and evaluated  a pulsatile  drug delivery system
based on impermeable capsule body filled with theophylline pellets and sealed with
erodible polymer plug placed in the opening of capsule body.  Erodible plugs were
prepared by direct compression. Theophylline pellets were placed in the capsule by
congealing a meltable plug material  within the capsule opening.  The theophylline
pellets were prepared in four batches with PVP K30, water as binder solution and
evaluated for the surface morphology, particle size, drug content and invitro release
profile and from the obtained results; one best formulation was selected for further
fabrication of pulsatile capsule. Different hydrogel polymers were used as plugs, to
maintain a suitable lag period and it was found that the drug release was controlled by
the proportion of polymers used. The lag time prior to pulsatile drug release correlated
well with erosion properties of the plugs. Pulsatile drug release could be controlled by
the composition of the plug and thickness of the plug. Programmable pulsatile release
has been achieved from a capsule device over the period of 2–36 hours which is the
requirement of chronopharmaceutical drug delivery.
Shah V et al. (2010) 20 developed formula for multiple unit system for pulsatile drug
delivery of Salbutamol Sulphate which offered a solution for chronopharmacological
behavior  of  asthma,  extensive  first-pass  metabolism  and  necessity  of  night-time
dosing. Among five Batches Specific batch with 4% of cellulose acetate phthalate
(CAP) and 2% of ethyl cellulose (EC) gave late release than predetermined time. It
released its higher dose after 6 hours. So that batch SF2 is accurate batch for nocturnal
asthma according to pulsatile drug delivery system.
 Okuda T et al. (2010) 21 developed formulation of biodegradable nanofiber meshes.
Which  enabled  the   time-programmed  dual  release  in  a  single  formulation.
Multilayered  drug-loaded  biodegradable  nanofiber  meshes  were  designed  using
sequential electrospinning. First drug-loaded mesh (top), (ii) barrier mesh, (iii) second
drug-loaded mesh, and (iv) basement mesh (bottom). The drug release speed and
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 duration were controlled by features  of  the electrospun meshes such as the fiber
diameter and mesh thickness. Control of the timed release and retardation period of
the second drug was accomplished by appropriate design of the barrier mesh 
thickness.  An  invitro  release  experiment  demonstrated  that  the  tetra-layered
construction  described  above  with  appropriate  morphological  features  of  each
component mesh can provide timed dual release of the respective drugs. The time
programmed dual release system using the multilayered electrospun nanofiber meshes
proved  to  be  useful  formulation for  multidrug combination therapy which  require
regiospecific  administration  of  two  drugs  at  different  times.  These  multilayered
formulations can be used for  biochemical modulation. That gives one administrative
strategy for use of sequential chemotherapy employing multiple anti-tumor drugs. 
 Iskandar S. Moussa, Louis H. Cartilier (1997)  22developed cross-linked amylose
(CLA)  press  coated  sustained  drug  delivery  design  dry  coated  tablets  for  time
independent and complex drug release. To make the cores, CLA was mixed with the
model  drug  in  different  proportions  and  then compressed.  The cores  were  coated
manually, consisting of either pure CLA or a mixture of CLA with a small proportion
of solute. Diltiazem HC1 and acetaminophen were the model drugs used. CLA dry
coated tablets behave as reservoir systems where the outer gel layer acts as a solution
diffusion membrane, through which transport occurs by a process of dissolution of the
permeating drug in the polymer at one interface and diffusion down a gradient in
thermodynamic  activity.  After  the  drug  has  established  a  uniform  concentration
gradient within the outer membrane (lag time), drug release is linear for the range of
constant  thermodynamic  activity  in  the  core.  For  the  same  core  composition,
decreasing the coating thickness or incorporating small amounts of NaC1 in the shell
shorten the release lag time and increase the release rate. By varying the drug to CLA
ratio  in  the  core  we  are  able  to  optimize  the  release  profiles.  Zero  order  release
profiles with or without a time delay were developed.
Efentakis M. et al (2006) 23 developed  a dry coated drug deliverdy system with an
impermeable cup, swellable top layer  and pulsatile release.  The system consists of
three different parts, a core tablet, containing the active ingredient, an impermeable
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 outer shell and a top cover layer barrier of a soluble polymer. The core contained
either diclofenac sodium or ketoprofen as model drugs. The impermeable coating cup
consisted  of  cellulose  acetate  propionate  and  the  top  cover  layer  of  hydrophilic
swellable  materials,  such  as  polyethylene  oxide,  sodium  alginate  or  sodium
carboxymethyl  cellulose.  The  effect  of  the  core,  the  polymer  characteristics  and
quantity at the top cover layer, on the lag time and drug release was investigated. The
results showed the release of the drug after a certain lag time generally due to the
erosion  of  the  top  cover  layer.  The  quantity  of  the  material,  its  characteristics
(viscosity, swelling, gel layer thickness) and the drug solubility was found to modify
lag time and drug release. The lag time increased when the quantity of top layer 
increased,  whereas  drug  release  decreased.  The  use  of  sodium  carboxymethyl
cellulose resulted in the greatest swelling, gel thickness and lag time, but the lowest
drug release from the system. Polyethylene oxide showed an intermediate behaviour
while,  the  sodium alginate  exhibited  the  smallest  swelling,  gel  thickness  and  the
shortest lag time, but the fastest release. These findings suggest that drug delivery can
be controlled by manipulation of these formulations.
Yan Zhang (2003) 24 Prepare a novel pulsed release system based on bilayer coated
tablets  containing  an  osmotically  active  agent.  Hydroxy  propyl  methyl  cellulose
(HPMC) and the mixture of Eudragit RS and RL were applied as the swelling layer
and  semi permeable  outer  coat,  respectively. To examine  the  mechanism of  drug
release  from this  pulsed  release  system,  drug  release  behaviors  were  investigated
under conditions of various osmotic pressures. Both lag time and release rate were
dependent on the coating level and the osmotic pressure of the dissolution medium.
The swelling of tablets and the dynamics of water uptake during the dissolution were
investigated to further elucidate the mechanism of drug release. The osmotic active
agent  induces  a  continuous  water  influx  resulting  in  a  rapid  expansion  of  the
membrane. The subsequent formation of fractures leads to a fast drug release after an
initial  lag  time.  All  the  results  obtained  in  the  present  study  indicated  that  both
diffusion and osmotic pumping effect were involved in drug release from the device,
but the latter was more dominant. 
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Janugade B.  et al (2009)  25 formulated  an oral press coated tablet by using direct
compression and wet granulation method to achieve the predetermined lag time. This
press coated tablets containing montelukast sodium in the inner core was formulated
with an outer barrier layer by different compositions of hydrophobic polymer ethyl
cellulose  and  hydrophilic  polymer  low substituted  hydroxyl  propyl  cellulose.  The
effect of formulation composition on the barrier layer comprising both hydrophobic
and hydrophilic excipients on the lag time of drug release was investigated. It  was
observed  that  lag  time  decreases  with  increasing  concentration  of  low substituted
hydroxyl  propyl  cellulose.  Press  coated  tablets  coated  by dry mixing and  by wet
granulation showed variations in lag time. As compared to dry mixed blend method
wet granulation method gives less lag time. 
Kimberly  D.  et  al.  (2009)  26 evaluated  pulsatile  dosing  of  clarithromycin  and
amoxicillin  alone  or  combined  against  Streptococcus  pneumoniae  with  various
susceptibilities. Pulsatile amoxicillin when combined with clarithromycin was proved
to  be  superior to  8  or  12  h  dosing  intermediate  strain  and  was  identical  for  the
susceptible strain. 
Salunkhe A et al (2011) 11 prepared and evaluated a floating pulsatile drug delivery
system  of  metoprolol  tartrate.  The  prepared  floating  pulsatile  delivery  system
consisted of three different  parts  a core tablet  containing the active ingredient,  an
erodible  outer  shell  and  a  top  cover  buoyant  layer.  The  rapid  release  core  tablet
(RRCT) was prepared by using superdisintegrants along with active ingredients. Dry
coating of optimized RRCT was done by using different grades of hydroxy propyl
methyl  cellulose  (HPMC)  E5,  E15,  and  E50  and  upper  most  buoyant  layer  was
prepared with HPMC K15M and sodium bicarbonate. Formulations were evaluated
for  their  physical  characteristics,  drug  content,  invitro  disintegration  time,  drug
release profile, floating lag time, floating time and invivo X ray study. On the basis of
these  evaluation  parameters  it  was  found  that  optimized  floating  pulsatile  release
formulation (FPRT) F9 showed floating lag time of 4 min, floating time of 12 hrs and
release  lag  time  of  6  hrs.  The  F9  formulation  showed  compliance  with
chronotherapeutic objective of hypertension.
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Jagdale S et al (2010) 12 developed novel colon targeted tablet formulation  by press
coating rapidly disintegrating tablet of Atenolol with guar gum and Eudragit L100 as
barrier  layer.  The  entire  device  was  enteric  coated  so  that  variability  in  gastric
emptying  time  can  be  overcome  and  a  colon  specific  release  can  be  achieved.
Different  ratios  of  polymers  were  selected  to  achieve  suitable  lag  time  for  the
treatment of angina pectoris. Invitro release studies for prepared tablets were carried
out for 2 h in 0.1 N HCl, 3 h in pH 7.4 phosphate buffer and 6 h in simulated colonic
fluid. In vitro studies revealed that the tablet coated with guar gum and Eudragit L100
have limited drug release in stomach and small intestinal environment and released
maximum amount of drug in the colonic environment.
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3 AIM AND OBJECTIVE
     Aim   
To develop and evaluate  floating-pulsatile System for a cardiovascular drug,
Nifedipine; with a four-five hour delay in release after oral administration. So that the
dose  administered  at  bedtime,  drug  is  released  after  the  initial  delay  such  that
maximum plasma level occurs in the early morning hours, when the patient is most at
risk.
Objective 
1) Preformulation studies
2) Selection of the appropriate excipients
3) Formulation of pulsatile floating tablet
4) To evaluate and characterize the prepared formulations
5)  Stability studies of prepared optimized formulation
6) To study pharmacokinetics of pulsatile floating tablet
.    
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4 PLANE OF WORK
1. Literature Survey.
2. Formulation of  tablet
• Selection  of  superdisintegrant  &  excipients  which  is  used  in  core
tablet.
• Preparation of core tablet.
• Preliminary  batches  of  combined  buoyant  polymers  for  pulsatile
release tablets.
• Preparation of buoyant layer.
• Preparation of pulsatile release tablet.
3. Evaluation of all pulsatile release tablet: 
• Physical parameters (Friability test, Hardness test, Drug content study,
Loss on drying)
• Assay
• Dissolution testing
4. Selection of the optimized tablets.
5. To perform stability testing of the optimized formulations.
6. Pharmacokinetic study
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5. MATERIAL AND INSTRUMENTS
Table 5.1 Instruments list
Table 5.2: List of the material
Ingredients Grade Category Manufacturer
Nifedipine BP Active Polydrug
Crosscarmellose 
sodium
USP Superdisintegrant Western pharma
KYRON T314 BP Superdisintegrant Corel pharma.
Magnesium Stearate BP Lubricant Western pharma
Lactose BP Diluent Western pharma
HPMC K4M BP Polymer S D Fine Chemicals
Carboxymethyl
cellulose 
sodium(NaCMC)
BP Polymer S D Fine Chemicals
HPMC E15LV BP Polymer S D Fine Chemicals
HPMC K100M BP Polymer S D Fine Chemicals
Sodium bicarbonate BP Effervescent agent S D Fine Chemicals
Citric acid BP Buffering agent S D Fine Chemicals
5.1. DRUG PROFILE 27-29
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Instrument Make Model no.
Analytical Balance Shimadzu AUW220D
Balance NHBAAE LC-T
Sieves Retch --
Tablet compression machine Cadmach, Ahmedabad
Dissolution test apparatus Electro Lab TDT-08L
UV Spectrophotometer UB Varian Cary 100 scan EL 08053091
FTIR Spectrophotometer Varian 640-IR
pH meter Equip – tronics EQ 621
Stability Chamber Thermolab --
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 NIFEDIPINE
5.1. 1. Chemical Name          : Dimethyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-
                                                   dihydropyridine-3,5-dicarboxylate.
5.1.2. Chemical Formula      : C17H18N2O6
5.1.3. Molecular Weight         : 346.3 g/mol
5.1.4. Official status                : BP
5.1.5. Organoleptic Properties : Yellow, crystalline powder.
5.1.6. Chemical Structure : 
Fig 5.1: Chemical Structure Of Nifedipine
5.1.7. Physical properties
Table 5.3: Physical properties of Nifedipine BP
Nature and Description Yellow, crystalline powder.
Solubility
Practically insoluble in  water,  freely soluble
in acetone, sparingly soluble in ethanol.
Melting Point 171 °C-175°C.
Log p 1.82-2.49
Hygroscopicity Non-hygroscopic
        
5.1.8. Chemical properties  
Table No.5.4: Chemical properties of Nifedipine BP
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              Table No.5.5: Clinical pharmacological properties of Nifedipine BP
Therapeutic Class Antihypertensive
Mechanism of Action Nifedipine, prototype of the dihydropyridines, inhibits the
influx of  calcium ions into cardiac  and vascular  muscle
cells like diltiazem and verapamil. On the contrary to these
two  drugs,  nifedipine  reduces  the  peripheral  arterial
vascular  resistance and  releases  coronary  artery  spasms.
Nifedipine  thus  has  hypotensive  and  antianginal
properties.
 Route  of
Administration
Oral/ intravenous
Bioavailability 12%
Drug-Drug 
Interactions
Cimetidine  can  cause  a  reinforced  effect  of  nifedipine
through enzyme inhibition. Nifedipine can raise phenytoin
and theophylline plasma levels. Unfavourable interactions
with  betablockers  and  digoxin  have  been  suspected  but
were not confirmed clinically
BCS Classification Class II
Adverse Effects Nifedipine causes symptomatic side-effects in 20 to 30%
of the treated  subjects.  These are based primarily on its
vasodilating properties  and  can  be  reduced  through
combinations with beta-blockers. 5 to 12% complain about
headaches, hot flushes, paresthesias, palpitations, vertigo,
legedemas  and  gastrointestinal  problems.  Fatigue,
impaired reaction and orthostatic hypotension are not as
common.  Significant  deterioration  has  been  observed
repeatedly when nifedipine was used for  left  ventricular
failure.  Occasionally  nifedipine  causes  an  increase  of
myocardial ischemias.
5.1.10 Pharmacokinetic/ Pharmacodynamic data: 
Table No.5.6: Pharmacokinetic/ Pharmacodynamic data Nifedipine BP
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pH 6.8-7.4
Photosensitivity Photosensitive
Purity/Assay 98.0%  - 102.0%
UV absorption 236 nm
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T ½    (hr) 2-3
Bioavailability Great variability 
In Average 50%
Metabolism Hepatic
Route of Excretion
Renal
5.1.11. Over dosage
Several  cases  of  overdosage  have  been  reported,  some  leading  to  death.
Potential  signs  and  symptoms  associated  with  overdosage  with  Nifedipine  are
bradycardia, hypotension, bronchospasm, and cardiac failure.
5.1.12. Absorption and distribution
In  man,  absorption  of  Nifedipine  is  rapid  and  complete.  Plasma  levels
following  oral  administration  of  conventional  Nifedipine  tablets,  however,
approximate  50% of  levels  following  intravenous  administration,  indicating  about
50% first-pass metabolism. Nifedipine crosses the blood-brain barrier and has been
reported in the CSF in a concentration 78% of the simultaneous plasma concentration.
5.1.13. Metabolism 
 Nifedipine  is  metabolized  predominantly  by CYP2D5,  an  enzyme  that  is
absent in about 8% of Caucasians (poor metabolizers) and about 2% of most other
populations. CYP2D5 can be inhibited by a number of drugs. Concomitant use of
inhibiting  drugs  in  poor  metabolizers  will  increase  blood  levels  of  Nifedipine
several-fold, decreasing Nifedipine's cardioselectivity.
5.1.14. Elimination 
Elimination is mainly by biotransformation in the liver, and the plasma half
life  ranges  from  approximately  2  to  3  hours.  Less  than  1%  of  an  oral  dose  of
Nifedipine is recovered unchanged in the urine; the rest is excreted by the kidneys as
metabolites  that  appear  to  have  no  calcium  channel-blocking  activity.  Following
intravenous administration of Nifedipine, the urinary recovery of unchanged drug is 
approximately 10%. The systemic availability and half-life of Nifedipine in patients
with renal failure do not differ to a clinically significant degree from those in normal 
subjects.  Consequently,  no reduction  in  dosage  is  usually  needed  in  patients  with
chronic renal failure. 
5.2. EXCIPIENT PROFILE
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5.2.1.  Hypromellose 30-31
Synonyms Hydroxypropyl methylcellulose;
hypromellosum; Methocel;
Chemical Name Cellulose hydroxypropyl methyl ether
Molecular Weight 10 000–1 500 000.
Functional 
Category
Bioadhesive  material;  coating  agent;  controlled-release
agent;dispersing  agent;  dissolution  enhancer;  emulsifying
agent;  emulsionstabilizer;  extended-release  agent;  film-
forming  agent;  foaming  agent;  granulation  aid;  modified-
release  agent;  mucoadhesive;  release-modifying  agent;
solubilizing  agent;  stabilizing  agent;  suspending  agent;
sustained-release  agent;  tablet  binder;  thickening  agent;
viscosity-increasing agent
Solubility Soluble in cold water, forming a viscous colloidal
solution;  practically  insoluble  in  hot  water,  chloroform,
ethanol (95%), and ether, but soluble in mixtures of ethanol
and  dichloromethane,  mixtures  of  methanol  and
dichloromethane, and mixtures of water and alcohol.
Loss on Drying Not more than 5%
Density 0.341 g/cm3
Viscosity Methocel K4M: 4000 mPas
Methocel K100M: 100 000 mPas
Methocel E15 LV: 15 mPas
Stability and 
Storage Conditions
Hypromellose  powder  is  a  stable  material,  although  it  is
hygroscopic  after  drying.  Solutions  are  stable  at  pH 3–11.
Hypromellose powder should be stored in a well-closed
container, in a cool, dry place.
Incompatibilities Hypromellose is incompatible with some oxidizing agents
Applications Hypromellose is widely used in oral, ophthalmic, nasal, and
topical  pharmaceutical  formulations.  In  oral  products,
hypromellose  is  primarily  used  as  a  tablet  binder,  in  film-
coating, and as a matrix for use in extended release
tablet formulations.
5.2.2. Carboxymethylcellulose sodium 32-33
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Synonyms Akucell;  Aqualon  CMC;  Aquasorb;  Blanose;  Carbose  D;
carmellosum  natricum;  Cel-O  Brandt;  cellulose  gum;
Cethylose
Chemical Name Cellulose, carboxymethyl ether, sodium salt
Functional 
Category
Emulsifying  agent;  coating  agent;  stabilizing  agent;
suspending agent;  tablet  and  capsule  disintegrant;  viscosity-
increasing agent;water-absorbing agent.
Solubility Practically  insoluble in  acetone,  chloroform,  ethanol  (95%),
toluene,  and ether.  Insoluble in water,  but  swells to  form a
suspension.
Loss on drying Not more than 10%
Density 0.52 g/cm3
Viscocity 5–2000 mPa s
Stability and 
Storage Conditions
Carboxymethylcellulose  calcium  is  a  stable,  though
hygroscopic  material.  It  should  be  stored  in  a  well-closed
container in a cool, dry place.
Incompatibilities Carboxymethylcellulose sodium is incompatible with strongly
acidic solutions and with the soluble salts of iron and some
other metals, such as aluminum, mercury, and zinc. It is also
incompatible with xanthan gum. Precipitation may occur at pH
< 2, and also when it is mixed with ethanol (95%).
Applications Carboxymethylcellulose  sodium is  widely  used  in  oral  and
topical  pharmaceutical  formulations,  primarily  for  its
viscosity-increasing properties. Higher concentrations, usually
3–6%, of the medium-viscosity grade are used to produce gels
that can be used as the base for applications and pastes
5. 2 .3. Sodium Bicarbonate 34-35
Synonyms Baking soda; E500; Effer-Soda; monosodium carbonate; natrii
hydrogenocarbonas; Sal de Vichy
Chemical Name Carbonic acid monosodium salt
Molecular Weight 84.01
Functional 
Category
Alkalizing agent; therapeutic agent.
Loss on drying Not more than 0.25% 
Density (bulk) 0.869 g/cm3
Solubility Ethanol (95%):  Practically insoluble
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Ether              :  Practically insoluble
Water             :  1 in 11
                          1 in 4 at 1000C(a)
                          1 in 10 at 250C
                          1 in 12 at 180C
Stability and 
storage
At ambient temperatures, aqueous solutions slowly decompose
with partial conversion into the carbonate; the decomposition
is  accelerated  by  agitation  or  heat.  Aqueous  solutions  of
sodium bicarbonate  stored  in  glass  containers  may  develop
deposits  of  small  glass  particles.  Sediments  of  calcium
carbonate with traces of magnesium or other metal carbonates
have been found in injections sterilized by autoclaving; these
are  due  to  impurities  in  the bicarbonate  or  to  extraction  of
calcium  and  magnesium  ions  from  the  glass  container.
Sedimentation  may  be  retarded  by  the  inclusion  of  0.01–
0.02% disodium edetate. Sodium bicarbonate is stable in dry
air but slowly decomposes in moist air and should therefore be
stored in a well-closed container in a cool, dry place.
Incompatibility Sodium bicarbonate reacts with acids, acidic salts, and many
alkaloidal salts, with the evolution of carbon dioxide. Sodium
bicarbonate can also intensify the darkening of salicylates.
Application Recently, sodium bicarbonate has been used as a gas-forming
agent  in  alginate  raft  systems  and  in  floating,  controlled
release  oral  dosage  forms  for  a  range  of  drugs.
Therapeutically,  sodium  bicarbonate  may  be  used  as  an
antacid,  and  as  a  source  of  the  bicarbonate  anion  in  the
treatment of metabolic acidosis. Sodium bicarbonate may also
be  used  as  a  component  of  oral  rehydration  salts  and  as  a
source of bicarbonate in dialysis fluids.
 5 .2.4 Citric Acid Monohydrate 36-37
Synonym Acidum  citricum  monohydricum,  2-hydroxypropane-
1,2,3-tricarboxylic acid monohydrate
Chemical Name 2-Hydroxy-1,2,3-propanetricarboxylicacid monohydrate
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Molecular Weight 210.14
Functional Category Acidifying agent; antioxidant; buffering agent; chelating
agent;flavor enhancer; preservative
Density 1.542 g/cm3
Solubility Soluble 1 in 1.5 parts of ethanol (95%) and 1 in less than
1 part of water; sparingly soluble in ether.
Stability and Storage 
Conditions
Citric acid monohydrate loses water of crystallization in
dry  air  or  when  heated  to  about  400C.  It  is  slightly
deliquescent  in  moist  air.  Dilute  aqueous  solutions  of
citric  acid  may  ferment  on  standing.  The  bulk
monohydrate or anhydrous material should be stored in
airtight containers in a cool, dry place
Incompatibilities Citric acid is incompatible with potassium tartrate, alkali
and alkaline earth carbonates and bicarbonates, acetates,
and  sulfides.  Incompatibilities  also  include  oxidizing
agents,  bases,  reducing  agents,  and  nitrates.  It  is
potentially explosive in combination with metal nitrates.
On storage, sucrose may crystallize from syrups in the
presence of citric acid.
Applications primarily to adjust the pH of solutions. It has also been
used experimentally to adjust the pH of tablet matrices
in  enteric-coated  formulations  for  colon-specific  drug
delivery.  Citric  acid  monohydrate  is  used  in  the
preparation  of  effervescent  granules,  while  anhydrous
citric  acid  is  widely  used  in  the  preparation  of
effervescent tablets. Citric acid has also been shown to
improve the stability of  spray-dried insulin  powder in
inhalation formulations. In food products, citric acid is
used as a flavor enhancer for its tart, acidic taste. Citric
acid monohydrate  is  used as a sequestering agent  and
antioxidant  synergist.  It  is  also  a  component  of
anticoagulant  citrate  solutions.  Therapeutically,
preparations  containing  citric  acid  have  been  used  to
dissolve renal calculi.
5.2.5 Lactose monohydrate 38-39
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Synonyms lactosum  monohydricum;  Monohydrate;  Pharmatose;
PrismaLac; SacheLac; SorboLac;
SpheroLac; SuperTab 30GR; Tablettose
Chemical Name O-b-D-Galactopyranosyl-(1,4)-a-D-glucopyranose
monohydrate
Molecular weight 360.31
Loss on drying Less than 0.5%
Density (true) 1.545 g/cm3
Functional Category Dry  powder  inhaler  carrier;  lyophilization  aid;  tablet
binder;  tablet  and  capsule  diluent;  tablet  and  capsule
filler
Solubility Chloroform : Practically insoluble
Ethanol       : Practically insoluble
Ether           : Practically insoluble
Water          : 1 in 5.24
                      1 in 3.05 at 400C
                      1 in 2.30 at 500C
                      1 in 1.71 at 600C                
Stability and Storage 
Conditions
Mold growth may occur under humid conditions (80%
relative  humidity  and  above).  Lactose  may  develop  a
brown  coloration  on  storage,  the  reaction  being
accelerated by warm, damp conditions. The purities of
different lactoses can vary and color evaluation may be
important,  particularly  if  white  tablets  are  being
formulated. 
Incompatibilities A Maillard-type condensation reaction is likely to occur
between lactose and compounds with a primary amine
group to form brown, or yellow-brown-colored products.
The Maillard interaction has also been shown to occur
between  lactose  and  secondary  amine.  However,  the
reaction sequence stops with the formation of the imine,
and no yellow-brown coloration develops.
Applications Lactose is widely used as a filler and diluent in tablets
and capsules, and also used as a diluent in dry-powder
inhalation. 
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5.2.6 Magnesium Stearate 40-41
Synonyms Dibasic  magnesium  stearate;  magnesium  distearate;
magnesia  stearas;  magnesium  octadecanoate;
octadecanoic acid, magnesium
salt; stearic acid, 
Chemical Name Octadecanoic acid magnesium salt
Molecular Weight 591.24
Density (true) 1.092 g/cm3
Loss on drying Not more than 6%
Functional Category Tablet and capsule lubricant
Solubility Practically insoluble in ethanol, ethanol (95%), ether and
water;  slightly  soluble  in  warm  benzene  and  warm
ethanol (95%).
Stability and Storage 
Conditions
Magnesium stearate is stable and should be stored in a
well-closed container in a cool, dry place.
Incompatibilities Incompatible  with strong  acids,  alkalis,  and iron salts.
Avoid  mixing  with  strong  oxidizing  materials.
Magnesium  stearate  cannot  be  used  in  products
containing aspirin,  some vitamins,  and most alkaloidal
salts.
Application Magnesium stearate is widely used in cosmetics, foods,
and pharmaceutical formulations. It is primarily used as
a  lubricant  in  capsule  and  tablet  manufacture  at
concentrations between 0.25% and 5.0% w/w. It is also
used in barrier creams.
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5.2.7 Microcrystalline cellulose 42-43
                              
Synonyms Avicel  PH;  Cellets;  Celex;  cellulose  gel;  hellulosum
microcristallinum;  Celphere;  Ceolus  KG;  crystalline
cellulose
Functional Category. Adsorbent; suspending agent; tablet and capsule diluent;
tablet disintegrant
Loss on drying Not more than 7%
Density (true) 1.512–1.668 g/cm3
Solubility Slightly soluble in 5% w/v sodium hydroxide solution;
practically  insoluble  in  water,  dilute  acids,  and  most
organic solvents.
Stability and Storage 
Conditions
Microcrystalline cellulose is a stable though hygroscopic
material. The bulk material should be stored in a well-
closed container in a cool, dry place
Incompatibilities. Microcrystalline  cellulose  is  incompatible  with  strong
oxidizing agents
Applications Microcrystalline  cellulose  is  widely  used  in
pharmaceuticals,  primarily  as  a  binder/diluent  in  oral
tablet and capsule formulations where it is used in both
wet-granulation  and  direct-compression  processes.   In
addition to its  use as  a binder/diluent,  microcrystalline
cellulose  also  has  some  lubricant  and  disintegrant
properties that make it useful in tableting
5.2.8. Polacrilin potassium (KYRONT-314) 44
Synonyms Amberlite  IRP-88;  methacrylic  acid  polymer  with
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divinylbenzene,potassium salt; polacrilinum kalii.
Chemical Name 2-Methyl-2-propenoic acid polymer with divinylbenzene,
potassium salt
Functional Category Tablet and capsule disintegrant
Description Polacrilin  potassium  occurs  as  a  cream-colored,  odorless
and  tasteless,  free-flowing  powder.  Aqueous  dispersions
have a bitter taste.
Loss on Drying Not more than 10%
Density 0.48 g/cm3
Solubility practically insoluble in water and most other liquids,
although polacrilin resins swell rapidly when wetted.
Stability and Storage 
Conditions
Polacrilin potassium and other polacrilin resins are stable to
light,  air,  and  heat  up  to  their  maximum  operation
temperature;see  Table  II.  Excessive  heating  can  cause
thermal decomposition of the resins and may yield one or
more oxides of carbon, nitrogen, sulfur, and/or amines.
Applications Polacrilin potassium is a cation-exchange resin used in oral
pharmaceutical formulations as a tablet disintegrant.
Concentrations  of  2–10%  w/w  have  been  used  for  this
purpose although 2% w/w of polacrilin potassium is usually
sufficient.Other  polacrilin  ion-exchange  resins  have  been
used as excipients to stabilize drugs, to mask or modify the
taste  of drugs,  and in the preparation of sustained-release
dosage forms and drug carriers.  Polacrilin  resins  are also
used in the analysis and manufacture of pharmaceuticals and
food products.
5.2.9. Croscarmellose sodium 45-46
Synonyms Ac-Di-Sol;  crosslinked  carboxymethylcellulose  sodium;
Explocel; modified cellulose gum;Nymcel ZSX;  Pharmacel
XL; Primellose; Solutab; Vivasol.
Chemical Name Cellulose, carboxymethyl ether, sodium salt
Functional Category Tablet and capsule disintegrant.
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Solubility insoluble in water, although croscarmellose sodium rapidly
swells  to  4–8  times  its  original  volume  on  contact  with
water. Practically insoluble in acetone, ethanol and toluene.
Density 1.543 g/cm3 
Stability and Storage 
Conditions
Croscarmellose  sodium  is  a  stable  though  hygroscopic
material.A  model  tablet  formulation  prepared  by  direct
compression,  with  CCS  as  a  disintegrant,  showed  no
significant  difference  in  drug  dissolution  after  storage  at
30°C for 14 months. 
Incompatibilities The efficacy of disintegrants, such as CCS, may be slightly
reduced in tablet formulations prepared by either the wet-
granulation  or  direct-compression  process  that  contain
hygroscopic  excipients  such  as  sorbitol  CCS  is  not
compatible with strong acids or with soluble salts of iron
and  some  other  metals  such  as  aluminum,  mercury,  and
zinc.
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6.   EXPERIMENTAL WORK
6.1 SPECTROSCOPIC CHARACTERIZATION OF NIFIDEPINE:
6.1.1 UV Spectroscopy
6.1.1.1 Determination of λmax
Nifidepine (10mg)  was  accurately  weighed  and dissolved in  0.1  N HCl in
100ml of volumetric flask and final volume was adjusted to 100ml. The stock solution
(100µg/ml) was further diluted using distilled water to get serial dilutions (5 to 50
µg/ml).The  solution  was  kept  in  a  fused  silica  cuvette.  The  UV  spectrum  was
recorded in the range of 200-400 nm on UB Varian Cary 100 scan double beam UV
visible  spectrophotometer  at  1  cm,  slit  width.  The  spectrum  and  wavelength  of
maximum absorption were recorded. 
6.1.1.2. Preparation of Standard Curve:
Standard curves were prepared by dissolving 10mg nifidepine in 100ml of 0.1
N HCl.  The  stock  solution  (100µg/ml)  was  further  diluted  with  the  same  to  get
solutions in concentration range of 5 to 50 µg/ml. The absorbance of these solutions
was determined spectrophotometrically at  236 nm and Beer’s  Lamberts graph was
plotted using absorbance concentration data.
6.1.2. FTIR Spectrum interpretation12
The dry sample of  nifidepine was mixed and triturated with dry potassium
bromide. The KBr discs were prepared by compressing the powders at pressure of 5
tons for 5 min. in a hydraulic press. Scans were obtained at a resolution of 4 cm-1,
from 4000 to 600 cm-1   
6.2 Physicochemical parameters of the A.P.I. 47-48
6.2.1 Bulk Density
            Accurately weighed 25 g of test sample (Candidate drug) was taken and sifted
through #18 and transferred it to 100 ml graduated measuring cylinder. The volume of
mass (M) observed without compacting. Then unsettled apparent volume (V0) level
was noted. The bulk density ( ρ b ) was calculated by following formula
                                                    0b V/M=ρ                                            
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6.2.2 Tapped Density
           Accurately weighed 25 gm of candidate drug was screened through #18 and
transferred  to  a  100  ml  graduated  measuring  cylinder  without  compacting.  The
cylinder was placed on the USP tapped density tester and was mechanically tapped,
allowing it to drop under its own weight that provides a fixed drop from 14 ± 2 mm at
a  nominal  rate  of  300  drops  per  minute.  The  cylinder  was  tapped  for  500  times
initially and tapped volume V1 was measured to nearest graduated units. The cylinder
was tapped repeatedly for additional tapping for 750 times and tapped volume V2 was
noted to the nearest graduated unit. If the difference between the two volumes (V1 and
V2) is more than 2% then repeated tapping for 1250 times and tapped volume (Vt )
was noted. The tapped density ( ρ t ) was calculated by formula
                                                
VtM /=ρ
                                                
Where, – M- Mass of powder
            
6.2.3 Compressibility index
            The compressibility index is measure of the capacity of a powder to be
compressed. As such, they are measures of the relative importance of interparticulate
interactions. In a free flowing powder, such interactions are generally less significant,
and the bulk and tapped densities are closer in value. For poor flowing materials, there
are frequently greater inter-particulate interactions, and a greater difference between
the bulk and tapped densities are observed.                                    
Table No.6.1 Scale of flowability-by CI
Sr.No. Compressibility index
(%)
Flow
characteristic
1. < 10 Excellent
2. 11-15 Good
3. 16-20 Fair
4. 21-25 Passable
5. 26-31 Poor
6. 32-37 Very poor
7. >38 Very very poor
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The compressibility index is calculated as follows:
                                
100
V
VV
IndexilityCompressib
0
t0 ×=
-
                          
Where,
Vo = Bulk volume 
Vt = Tapped volume.
6.2.4 Hausner’s Ratio (H)
           This is an indirect index of ease of powder flow. Hausner’s Ratio is an 
indication of flowability of a powder.
 Table 6.2 Scale of flowability-by HR
Sr.No. Hausner’s
ratio
Flow
characteristic
1. 1.00-1.11 Excellent
2. 1.12-1.18 Good
3. 1.19-1.25 Fair
4. 1.26-1.34 Passable
5. 1.35-1.45 Poor
6. 1.46-1.59 Very poor
7. >1.60 Very very poor
 It is calculated by the following formula,    
t
0
V
V
=ratios'Hausner
                                          
                                                     Where, Vo - Bulk volume
                                                                  Vt - Tapped volume
6.3 Compatibility Study by DSC
          Five milligram of drug sample was accurately weighed and placed in the
hermetic aluminum DSC pan. The pan was sealed with the help of hydraulic press.
The sample was heated in DSC furnace  for programmed temperature  range  50 to
300oC at heating rate of 0.5oC/min. The nitrogen flux rate was set at 20 mL/min. The
study was performed using DSC6 instrument (Perkin Elmer, Germany). DSC studies
of nifidepine were carried out with each excipient. 
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Table no. 6.3 Drug-Excipients Compatibility Study 
Storage
40°C/75% RH 1
M open
40°C/75% RH
1 M closed
55°C
1 M open
Nifidepine Alone Alone Alone
Croscsrmalose sodium 
+Nifidepine
(1:1) (1:1) (1:1)
Kyron t 314+Nifidepine (1:1) (1:1) (1:1)
Magnesium stearate+Nifidepine (1:1) (1:1) (1:1)
Lactose+Nifidepine (1:1) (1:1) (1:1)
Hpmc k4m+Nifidepine (1:1) (1:1) (1:1)
Hpmc e 15 lv+Nifidepine (1:1) (1:1) (1:1)
Hpmc k 100+Nifidepine (1:1) (1:1) (1:1)
Sodium bicarbonate+Nifidepine (1:1) (1:1) (1:1)
Citric acid+Nifidepine (1:1) (1:1) (1:1)
Di calcium 
phosphate+Nifidepine
(1:1) (1:1) (1:1)
Microcrystsline 
celllose+Nifidepine
(1:1) (1:1) (1:1)
nifidepine  was  mixed  with  1:1  proportion  with  all  excipients  to  be  used  in  our
formulation. and kept at 40°C/75% RH (close),  55°C (close), 55°C (open) for one
month.  Thermograms  were  obtained  after  a  month  by  DSC study  confirmed  the
compatibility of the excipients with the A.P.I.
6.4 PHYSICOCHEMICAL PARAMETERS OF POWDER BLEND47
6.4.1 Particle size analysis of powder blend by Sieving method 
            This test was performed with the help of sieves of different size. They were
fitted in the platform of sieve shaker in such a way that the coarse sieve was placed on
top corresponding to the finer sieves. Placed 50 gm sample on the top and run the
machine  for  5  min.  and  took  the  weight  of  the  retention  on  the  sieve(s).Finally
calculated the % of retention on each sieve by the following equation.
100
50
retention ofquantity 
  retained % X=
6.4.2 Bulk density of powder blend
          A known quantity of powder was poured into the measuring cylinder carefully
level the powder without compacting,  if necessary and read the unsettled apparent
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volume, Vo, to the nearest graduated unit. Calculate the bulk density, in gm per ml, by
the formula 
Bulk density = Bulk Mass/ Bulk Volume
6.4.3 Tapped density of powder blend
        After observing the initial volume, the cylinder is mechanically tapped and
volume readings  are  taken  until  little  further  volume  changes  observed.  Cylinder
dropping distance: 14± 2 mm at a normal rate of 300 drops / minute. Unless otherwise
specified, tap the cylinder 500 times initially and measure the tapped volume, VA, to
the nearest graduated unit. Repeat the tapping an additional 750 times and measure
the tapped volume, Vb, to the nearest graduated unit. If the difference between the
two volumes is less than 2%, Vb is the final tapped volume, Vf. Repeat in increments
of 1250 taps, as needed, unit the difference between succeeding measurements is less
than 2%. Calculate the tapped density, in gm per ml, by the formula
Tapped Density = Vf
m
6.4.4 Measurement of Powder Compressibility
           The compressibility index and Hausner’s ratio are measures of the propensity
of a powder to be compressed. As such, they are measures of the relative importance
of  inter  particulate  interactions.  In  a  free  flowing  power,  such  interactions  are
generally  less  and  tapped  densities  will  be  closer  in  value.  For  poorer  flowing
materials,  there  are  frequently  greater  inter  particle  interactions,  and  a  greater
difference between bulk and tapped densities will be observed. These differences are
reflected  in  the  compressibility  Index  and  the  Hausner’s  ratio  calculated  by  the
formula
Compressibility index: = 
0
0 )(100
V
VfV −
Hausner’s Ratio: = Vf
V0
6.4.5 Loss on drying
          Crush the tablet with the help of mortar and pestle. Take crucible and keep in
drying oven at 105°C for half an hour. Cool at room temperature in a desiccator for 30
minutes.  Weigh  accurately  empty  bottle,  add  2  g  of  powder  into  it  and  weigh.
Distribute the sample as evenly as practicable by gentle sidewise shaking to a depth 
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not exceeding 10 mm. Place the LOD bottle in the drying oven at 105°c by for four
hours. After drying is completed, open the drying oven, close the crucible carefully 
and allow it to cool at  room temperature in desiccator  for  30 minutes.  Weigh the
crucible and calculate the percentage LOD.
Calculation
Wt. of empty crucible (W1)    
Wt. of crucible + sample (W2) 
Wt. of sample (W2-W1)
Wt. of crucible + sample after drying (W3) 
           Loss in wt. of sample after drying (W2-W3): 
                                        (W2 - W3)
           LOD (% w/w) =                                 x        100 
                                         (W2 - W1)
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6.5 FORMULATION AND DEVELOPMENT OF FLOATING PULSATILE 
DRUG DELIVERY SYSTEM OF NIFIDEPINE 11
Fig 6.1: Process Flow Chart
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6.5.1 Preparation of the Rapid Release Tablet (RRT) 11
          The inner core tablets were prepared by using direct compression method.
Different preliminary batches  of core tablets were taken in to fix concentration of
superdisintegrant in tablet.  Concentration of super disintegrants varies from 1 to 4
mg/tablet.  Powder  mixtures  of  nifidepine,  crosscarmellose  sodium  (Ac-Di-Sol),
KYRON T314, lactose and ingredients were dry blended for 20 min. followed by
addition of magnesium stearate. The mixtures were then further blended for 10 min,
60 mg of resultant powder blend (theoretically equivalent to 20 mg of nifidepine) was 
compressed using rotary tabletting machine (Cadmach Machinery, Ahmedabad, India)
with a 6mm punch and die to obtain the core tablet.                                    
                                 Table 6.4: Formulations of core tablet
Evaluation of the Rapid Release Tablet (RRT)
Determination of Drug Content 
         Total 10 tablet were weighed and powder equivalent to 25 mg of  Nifidepine
was weighed and dissolved in methanol then filtered through Whatman filter paper.
Solution  was  analysed  for   content  by  UV-Spectrophotometer  at  236  nm  using
methanol as blank.
Disintegration test
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Ingredients
(mg) I II III IV V VI VII VIII
Nifidepine (mg) 20 20 20 20 20 20 20 20
CCS(mg) 1 2 3 4 - - - -
KYRON T 
314(mg)
- - - - 1 2 3 4
Mg-Stearate(mg) 8 8 8 8 8 8 8 8
Lactose(mg) 31 30 29 28 31 30 29 28
TOTAL (mg) 60 60 60 60 60 60 60 60
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        The tablet was put into 100 ml distilled water at 37 ± 2oC. Time required for
complete  dispersion  of  a  tablet  was  measured  with  the  help  of  a  digital  tablet
disintegration test apparatus.
Hardness test
          Pfizer hardness tester was used for the determination of hardness of tablets. The
tablet was placed in contact between the plungers and handle was pressed. The force
of fractured  was recorded.
Friability test    
The  friability  of  all  the  tablets  studied  was  determined  using  a  Roche
friabilator. In the disinteration time study,
 From above study two batches II and VI were selected as optimized batches. 
 6.5.2 Preparation of the Floating and Pulsatile Release Tablet (FPRT) 11
           FPRT was designed to comprise PRT and top cover buoyant layer. PRT was
taken as the layer for pulsatile release.
6.5.2.1 Preparation of the Pulsatile Release Tablet (PRT)
           Each powder used as erodible outer shell i.e. HPMC K4, HPMC E15 LV,
carboxy methylcellulose sodium (NaCMC) was passed through a 500µm.  RRT was
taken as core.  Studies were carried out on different combination of polymers, which
were considered as preliminary batches. Dissolution study was carried out for above
batches and by observing result it was necessary to carry out experiment on individual
polymers.
Table  6.5:  Addition  of  polymer  for  pulsatile  release  tablet  containing
crosscarmellose sodium
Sr
No.
Ingredients Formulation Codes
C1 C2 C3 C4 C5 C6 C7 C8 C9
1 HPMC K4 M 140 160 180 - - - - - -
2 NaCMC
- - - 140 160 180 - - -
3 HPMCE15 LV
- - - - - - 230 260 290
Table 6.6: Addition of polymer for pulsatile release tablet containing       
KYRON T314
Ingredients                             Formulation Codes
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K1 K2 K3 K4 K5 K6
1 HPMC K4 M 140 160 180 - - -
2 HPMCE15 LV - - - 230 260 290
           
           For HPMC K4, 60 mg of powder was filled in a die followed by RRT in the
center of die. Slightly pressed the tablet to fix the coatings around and under the core,
then the rest of the coatings was filled and compressed. Same procedure was applied
to rest of the powders i.e. for HPMC E15LV and NaCMC. For the above batches
dissolution study was conducted from which optimized batches  were  selected  and
only that batches were conducted for further study.
6.5.2.2 Compositions of the Buoyant Layers
       The compositions of the buoyant layer of the FPRT for floating testing were
shown in Table 6.8. All powdered excipients were mixed for 5 min using a mortar and
pestle to form a homogenous directly compressible powder mix. Different fillers were
used to adjust the tablet weight and effect of fillers on floating time was observed.
For the preparation of FPRT tablet, batch K3 and K6 were used in compression with
buoyant layer. 
Table 6.7: Compositions of the Buoyant Layers
Sr
No.
Ingredients
Formulation codes
F1 F2 F3 F4 F5
1 HPMC K 100M 150 150 150 150 150
2 Sodium bicarbonate 20 40 80 40 20
3 Citric acid 20 40 80 40 20
4 Dicalcium phosphate 20 - - - -
5
Microcrystalline
cellulose
- 20 - - -
6 Lactose - - 20 20 20
6.6 EVALUATION OF FLOATING AND PULSATILE RELEASE TABLET 47-48
6.6.1 Physical evaluation
6.6.1.1 Friability test
      The friability of all the tablets studied was determined using a Roche friabilator.
6.6.1.2 Hardness test:
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          Pfizer hardness tester was used for the determination of hardness of tablets.The
tablet was placed in contact between the plungers and handle was pressed.The force
of fractured was recorded.
6.6.1.4 Determination of Drug Content:
          Total 10 tablet were weighed and powder equivalent to 20 mg of nifidepine was
weighed  and  dissolved  in  methanol  then  filtered  through  Whatman  filter  paper.
Solution was analysed for nifidepine content by UV Spectrophotometer at 236 nm
using methanol as blank
6.6.1.5 In Vitro Buoyancy Determination 11
          Floating behavior  of  the tablet  is  determined by using USP dissolution
apparatus II in 500 ml of 0.1 N HCl which is maintained at 37±0.5°C, rotated at 50
rpm. The floating lag time as well as total floating time is observed.
6.6.1.6 Swelling Index determination
         Tablets were weighed individually (designated as W1) and placed separately in
glass beaker containing 200 ml of 0.1 N HCl and incubated at 37°C±1°C. At regular
1-h time intervals until 24 h, the tablets were removed from beaker, and the excess
surface liquid was removed carefully using the paper. The swollen tablets were then
re-weighed (W2) and swelling index (SI) was calculated using the following formula:
                              SI =   W2-W1   X 100    --------------------------- (6.1)  
                                            W1
6.7 DISSOLUTION STUDIES 11
Parameters
Dissolution media                              -0.1 N HCl,
Volume of Dissolution medium         - 900 ml,
RPM                                                   - 50,
Temperature of dissolution mediu     - 37.0 ± 0.50C,
Apparatus type                                   - USP Apparatus II.
         A sample (5 ml) of the solution was withdrawn from the dissolution apparatus
hourly for 15 hours, and the samples were replaced with fresh dissolution medium.
The samples were filtered through a 0.45-µ membrane filter and diluted to a suitable
concentration with 0.1N HCl. Absorbance of these solutions was measured at 236 nm
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using Varian cary-100 double beam UV spectroscopy.  Cumulative percentage drug
release was calculated using an equation obtained from a standard curve.
6.8 STABILITY TESTING OF THE OPTIMIZED FORMULATION
           Temperature dependent stability studies were carried out on the optimized
batch. They were packed in low density polyethylene (LDPE) bags enclose in high
density polyethylene (HDPE) container and stored under the following conditions for
a period as prescribed by ICH guidelines for accelerated studies. 
(I) 30 + 2 o C and RH 65 % + 5%
(II) 40 + 2 o C and RH 75 % + 5% 
Tablets were withdrawn after a period of 7, 14 days, 1, 2, 3 months and analyzed for
physical  characterization  (appearance,  moisture  content),  dissolution  study  and
percentage assay. 
6.9 DRUG RELEASE MECHANISM FROM MATRICES 49-51
        The mechanism of drug release has been proposed that drug release from the
matrices  usually  implies  water  penetration  in  the  matrix,  hydration,  swelling,
diffusion of  the dissolved drug (polymer  hydro fusion),  and  or  the erosion of  the
gelatinous layer. However, it is worth mention that the release mechanism of a drug
would depend on the dosage form selected, pH, and nature of the drug and, of course,
the polymer used.
6,9.1. Zero order kinetics 
Drug dissolution from pharmaceutical  dosage from that do not disaggregate
and release the drug slowly (assuming that area does not change and no equilibrium
conditions are obtained) can be represented by the following equation.
W0 –Wt = Kt 
Where, W0 = initial amount of drug in the pharmaceutical dosage form,
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            Wt = amount of drug in the pharmaceutical dosage form,
             t =    time,
            K = Proportionality constant.
The  pharmaceutical  dosage  form  following  this  profile  release  the  same
amount of drug by unit  of  time and in  this model can be explained by following
equation                               
                              Qt = Q0 + K0t      
                              Where, Qt = Drug dissolved in time t, 
                                        Q0 = Initial amount of drug in solution,
                                       K0 = Zero order rate constant
6.9.2. First order kinetics
            The application of this model to drug dissolution studies was first proposed by
Gibaldi and Feldman (1967) and later by Wagner. The dissolution phenomena implies
a surface action, as can be seen by Noyes–Whitney equation,
)( CCK
dt
dc
s −=  
                               Where,   C = Concentration of solute in time t,
                                           CS = solubility in equilibrium at experience temperature.
                                             k =First order proportionality constant
Hixson and Crowell adapted the above equation as 
)( CCKS
dt
Dw
s −=  
                             Where, w = amount of solute in solution at time t,
                                        S = Solid area accessible to dissolution.
                         log Qt = log Q0 + K1.t / 2.303  
                                   Where, Qt = amount of drug release in time t, 
                                              Q0 = initial amount of drug in solution,
                                    K1 = First order release constant.
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Above equation also represents this model.
The pharmaceutical  dosage  form following this  dissolution profile,  such as
those  containing water soluble drugs in porous matrices release drug in a way that is
proportional to amount of drug remaining in its interior in such a way that amount of
drug released by unit of time diminish.
6.9.3 Higuchi Model
Higuchi developed mathematical expressions for drugs particles dispersed in a
uniform matrix behaving as diffusion media. To study the dissolution form a planar
system having a homogeneous matrix, the relation obtained was
tCCCQft SS )2( −==
Where, Q = Amount of drug released in time t per unit area.
           C = Drug initial concentration
          CS = drug solubility in matrix media 
           D = Diffusivity of drug molecules in matrix substance.
Fig.6.2:  Drug  theoretical  concentration  profile  of  a  matrix  system  in  direct
contact with a perfect sink release media.
The solid line represents the variation of drug concentration in the pharmaceutical
system  after  time  t.  To  distance  h,  the  concentration  gradient  will  be  constant,
provided C>> Cs. The linearity order follows the Fick’s law.
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)2( SS CCtDCQ −=   
Relation is valid during all time except when the total depletion of drug in
therapeutic  system is  achieved  .Higuchi  developed  other  models  for  release  from
heterogeneous  matrix,  when  the  drug  concentration  in  matrix  is  lower  than  its
solubility and the release occurs through pores in matrix, the obtained relation is:
ft = tCCC
T
DEQ SS )2( ε−=
6.9.4 Korsmeyer and peppas model 
This equation is useful to study the diffusion / relaxation release of dosage
form as well zero order release kinetics. The equation can be described as  
nt Kt
M
M
=
∞
 
Where, ∞M
M t
 = fraction of drug release in time t, 
                           K = constant incorporating structural and geometric 
             characteristics of controlled release device.
                          n = diffusion release exponent indicative of release mechanism.
For release from swellable cylinders Ritger and Peppas have indicated, 
                    n = 0.45 for Fickian diffusion, 
                    n > 0 .45 and < 0.89 for anomalous diffusion or non Fickian 
diffusion  (0.5 < n < 1)
                    n = 0.89 for zero order release 
                    n = 1 or > 1 for super case
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7. RESULTS AND DISCUSSION
7.1 CHARACTERIZATION  AND  PREPARATION  OF  CALIBRATION
CURVE OF NIFEDIPINE
7.1.1 UV Spectroscopy
Determination of λ max and preparation of standard curve
       The UV spectrum obtained is shown in  Fig.7.1. The wavelength of maximum
absorbance (λ  max.) was found to be at  236 nm for 0.1 N HCl (Simulated gastric
Fluid) solutions. Using absorbance-concentration data; calibration curve was plotted
and is shown in Fig. 7.2. The plot of Absorbance v/s Concentration (µg/ml) was found
to be linear in the concentration range of 0 to 50 µg/ml and obeys the Beer-Lambert’s
law in the same ranges.
Fig 7.1:
                            Fig. 7.2: Calibration Curve of Nifedipine 
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               where y 
is the absorbance and x is the concentration (µg/ml)
7.1.2 IR Spectrum Interpretation
The IR spectrum of Nifedipine is shown in Figure. 7.3
The interpretation of IR frequencies is done and shown in Table 7.1
Fig.7.3: IR Spectrum of Nifedipine 
Table 7.1: IR Spectrum of Nifedipine
Groups Range (1/cm)
N-H 3325
C=O 1680
C=C 1650
NO2 1530,1350
Aromatic ring 1515-1580
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Parameters Value
Beer’s law limit (µg/ml)236 nm
Wavelength of  detection (nm)
0 – 50
Regression Equation (y = mx + c) 1
Slope (m)
0.0041Intercept (c) 0.0015
Correlation coefficient 0.9997
                                                                                                                            
Result and Discussion 
7.2 Physicochemical parameters of the A.P.I.
7.2.1 Physical characterization of candidate drug
                     Table No.7.2: Physical properties of candidate drug
The data shows
that nifedipine is poor flowing. 
7.3 Compatibility Study by DSC
7.3.1 DSC analysis of pure nifedipine 
    The drug showed sharp endotherm at 172.41oC with starting at  172.14oC. The
reported value is 172.5oC. The DSC thermo gram is presented in Figure No.7.4
                                   Figure No.7.4: DSC analysis of Nifedipine
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Bulk density (g/ml) 0.235
Tapped density (g/ml) 0.423
Carr’s index (%) 44.44
Hausner ratio 1.80
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7.3.2  The thermo gram obtained By The D.S.C  technology with nifedipine and  
KYRON T 314
 
Fig no.7.5  Thermogram of  nifedipin and KYRON T 314
No significant change is observed in melting point.
7.3.3  The thermo gram obtained By The D.S.C  technology with nifedipine and  
croscsrmalose sodium 
Fig no.7.6 Thermogram of nifedipine  and  croscarmellose sodium
No significant change is observed in melting point.
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7.3.4 The thermo gram obtained By The D.S.C  technology with nifedipine and   
magnesium stearate
Fig no.7.7 Thermogram of nifedipine and magnesium stearate 
No significant change is observed in melting point.
7.3.5 The thermo gram obtained By The D.S.C  technology with nifedipine and   
lactose
Fig no.7.8  Thermogram of nifedipine and lactose
No significant change is observed in melting point.
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7.3.6 The thermo gram obtained By The D.S.C  technology with nifedipine and 
HPMC K 4M        
Fig no.7.9  Thermogram of nifedipine and HPMC K 4M
No significant change is observed in melting point.
7.3.7 The thermo gram obtained By The D.S.C  technology with nifedipine and 
HPMC E 15 LV       
Fig no.7.10  The thermo gram obtained By The D.S.C  technology with 
nifedipine and HPMC E 15 L
No significant change is observed in melting point.
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7.3.8 The thermo gram obtained By The D.S.C  technology with nifedipine and   
 HPMC K  100
Fig no.7.11  The thermo gram obtained By The D.S.C  technology with 
nifedipine and HPMC K 100
No significant change is observed in melting point.
7.3.9 The thermo gram obtained By The D.S.C  technology with nifedipine and   
sodium bicarbonate
Fig no.7.12  The thermo gram obtained By The D.S.C  technology with 
nifedipine and sodium bicarbonate
No significant change is observed in melting point.
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7.3.10  The thermo gram obtained By The D.S.C  technology with nifedipine and
citric acid
Fig no.7.13  The thermo gram obtained By The D.S.C  technology with 
nifedipine and  citric acid
 No significant change is observed in melting point.
7.3.11 The thermo gram obtained By The D.S.C  technology with nifedipine and 
di calcium phosphate
Fig no.7.14 Thermogram of  nifedipine and  di calcium phophate
No significant change is observed in melting point.
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7.3.12 The thermo gram obtained By The D.S.C  technology with nifedipine and 
Microcrystaline cellulose
 
Fig no.7.15 Thermogram of nifedipine and microcrystalline cellulose
No significant change is observed in melting point.
7.4 PHYSICOCHEMICAL PARAMETERS OF POWDER BLEND
7.4.1 Particle size analysis of powder blend by Sieving method
       Particle size distribution (PSD) of granules was performed using sieve analysis
with different mesh size.         
            Table 7.3: Particle size Distribution  data lubricated granules
Trial 
No.
Cumulative percent sample retained (%)
 
 
 
30 # 40# 60# 80# 100# Collector
1 47.52 64.84 75.72 88.44 92.36 100.00
2 16.42 32.405 45.64 60.45 70.73 100.00
3 31.20 75.64 75.68 76.48 85.64 100.00
4 16.40 32.40 45.64 60.44 70.76 100.00
5 40.52 58.54 65.55 81.20 91 35 100.00
6 35.21 80. 20 81.56 86.23 94.23 100.00
7 8.16 35.56 92.28 92.32 92.44 100.00
8 05.23 38.23 55.44 79.04 92.68 100.00
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7.4 Analysis of powder blend for density and LOD
Trial 
No.
LOD 
(%L)
Granules
Bulk 
density 
(gm/ml)
Tapped 
density
(gm/ml)
Compressibility
index
Hausner’s
ratio
1 0.65 0.440 0.480 8.33 1.09
2 0.68 0.467 0.565 17.39 1.11
3 0.68 0.510 0.520 13.95 0.98
4 0.68 0.456 0.543 16.03 1.19
5 0.58 0.446 0.536 16.79 1.20
6 0.68 0.456 0.543 16.03 1.19
7 0.68 0.456 0.521 12.26 1.14
8 0.86 0.456 0.543 16.03 1.19
7.5 EVALUATION OF RAPID RELEASE TABLET (RRT)
Table 7.5: Evaluation of RRT
Formulation Hardness
Kg/cm2
Friability
(%)
Drug Content
(mg%)
Disintegration
Time(S)
I 3.8 0.62±0.12 99.22 45
II 3.4 0.69±0.14 98.92 11
III 3.7 0.65±0.11 99.85 30
IV 3.8 0.62±0.11 99.72 28
V 3.6 0.60±0.14 99.35 24
VI 3.2 0.67±0.13 99.97 11
VII 3.9 0.63±0.16 99.65 49
VIII 3.6 0.60±0.11 99.78 10.4
             In all formulation, the hardness test indicated good mechanical strength,
whereas friability is less than 1% which indicated that tablet had good mechanical
resistance.Drug  content  was  found  to  be  high  (>99.20)  and  uniform in  all  tablet
formulations.  It  was  ranged  from  98.92  to  99.85  and  uniform  in  all  tablet
formulations. Absorption maxima was determined by scanning different concentration
of solution of drug Nifedipine. Absorption maxima was 236 nm and method obeys
Beer's  law in concentration range 0 to 50 µg/ml, with good correlation coefficient
(0.9997).When a standard drug solution was assayed repeatedly (n=6),relative error 
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(accuracy) and relative standard deviation (precision) were found to be 0.72 and 0.93
% respectively. The tablets were subjected for evaluation of the in-vitro disintegration
time and it was observed that the time for formulation varied from 10 to 52 second. It
was  observed  that  the  time for  formulation  varied  from 10  to  52  second.  It  was
observed that when KYRON T314 was used as disintegrant, tablet was disintegrate
within short time due to easy and high swelling ability of KYRON T314 as compared
to CCS. It is observed that disintegration time of tablet decreased with increased in
concentration  of  CCS  and  KYRON  T-314.  But  by  disintegration  study  it  was
observed  that  hardness  plays  important  role.  For  development  of  pulsatile  release
study disintegration time must be short to obtain burst effect  therefore having less
hardness. Hence by observing results it was concluded that batches II and VI were
optimized batches which was confirmed by dissolution study. 
7.5.1 Dissolution Study Of Rapid Release Tablet (RRT)
Table 7.6: Dissolution testing of Batch I-IV
Time
(min)
% Drug Release
I II III IV
0 0 0 0 0
1 48.84 49.23 53.43 54.78
2 55.67 57.87 62.49 65.98
3 63.87 66.9 69.45 70.1
4 68.93 70.92 74.82 76.9
5 77.68 79.99 82.56 83.76
6 83.56 86.79 88.93 89.92
7 88.94 90.56 92.39 93.44
8 94.69 97.84 98.7 99.45
9 98.95 98.9 99.28
10 99.87 99.99 100.09
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Fig 7.16: Dissolution testing of Batch I-IV
                                 Table 7.7: Dissolution Testing of batch V-VIII 
Time
(min)
% Drug Release
V VI VII VIII
0 0 0 0 0
1 50.26 55.9 54.87 54.37
2 54.98 69.78 62.93 60.23
3 61.03 75.98 67.4 63.45
4 68.9 83.56 76.79 78.98
5 79.97 89.91 83.59 86.73
6 84.78 93.45 89.99 90.17
7 90.83 97.99 94.98 95.68
8 95.98 100.2 99.9
9 99.58 100.09
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                          Fig.7.17:  Dissolution Testing of batch V-VIII
       From above two graphs it  was cleared that Rapid increase in dissolution of
nifedipine  with  increase  in  KYRON 314 may be  attributed  to  rapid  swelling  and
disintegration  of  tablet  into  primary  particles.  CCS  exhibit  capillary  activity  and
pronounced hydration, with little tendency of gel formation and disintegrate the tablet
rapidly but into larger masses of aggregated particle and later resulting in slow release
of drug.
7.6  EVALUATION  OF  THE  FLOATING  AND  PULSATILE  RELEASE
TABLET (FPRT):
It was observed that the disintegration time for formulation varied from 10 to
52 second. It was observed that when KYRON T314 was  used as disintegrant, tablet
was disintegrate within short time due to easy and high swelling ability of KYRON
T314  as compared to CCS. It is observed that disintegration time of tablet decreased
with increased in concentration of CCS and KYRON T-314. But by disintegration
study it was observed that hardness plays important role. For development of pulsatile
release study disintegration time must be short to obtain burst effect therefore having
less hardness. Hence by observing results it  was concluded that batches II  and VI
were optimized batches which were confirmed by dissolution study.
7..6.1 Pulsatile Release Tablet (PRT)
         For this study, the core tablets containing nifedipine (RRT) were compression
coated  with  different  powder  such  as  HPMC  K4,  HPMC  E15LV,  sodium
carboxymethylcellulose, used as outer erodible shell. Dissolution studies were carried 
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out  on  combination  of  polymers  as  well  as  on  individual  polymers.  Dissolution
studies  resulted  that  batches  prepared  with  combined  polymers  formed  too  sticky
mass to release the drug when polymers came into contact with dissolution medium.
From this it was resulted that combined polymers are not suitable for pulsatile drug
delivery  system  Core  tablet  containing  crosscarmellose  sodium was  compression-
coated with HPMC K4, HPMC E15LV, sodium carboxymethylcellulose and these
batches were taken as preliminary batches for the study of individual polymers. The in
vitro  release  profiles  of  nifedipine  from  different-coated  systems  in  0.1  M  HCl
solution was provided in Figure 7.18,7.19, 7.20.
                                Table 7.8: Dissolution Testing of batch C1-C3
Time (hrs) % Drug Released
C1 C2 C3
0 0 0 0
1 0 0 0
2 5 3 0
3 10.95 5.67 0
4 25.4 7.45 0
5 38.81 24.87 0
6 49.86 39.66 8.01
7 66.54 50.32 25.03
8 78.24 67.53 43.56
9 96.9 88.27 65.75
10 99.61 94.93 80.55
11 98.88 89.6
12 99.97 95.38
13  98.3
14 99.57
15 99.15
16 99.56
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Fig 7.18: In vitro release profiles of Nifedipine from the pulsatile release tablet
(PRT) coated with different amount of HPMC K4M.
                             
Table 7.9: Dissolution Testing of batch C4-C6
Time (hrs.) % Drug Released
C4 C5 C6
0 0 0 0
1 0 0 0
2 27.91 0 0
3 52.39 30.87 24.97
4 64.98 51.9 41.74
5 78.49 68.76 65.89
6 90.72 80.95 79.8
7 95.69 91.69 90.98
8 98.19 96.98 96.5
9 99.85 99.81 99.78
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10 99.89 99.96
11 99.95
Fig 7.19: In vitro release profiles of Nifedipine from the pulsatile release tablet
(PRT) coated with different amount of NaCMC in 0.1 M HCl.  
                        
                      
Table 7.10: Dissolution Testing of batch C7-C9
Time (hrs.) % Drug Released
C7 C8 C9
0 0 0 0
1 0 0 0
2 20 0 0
3 27.98 5.98 0
4 51.54 15.9 5.98
5 65.89 29.87 30.98
6 77.97 45.76 50.39
7 83.78 53.21 67.29
8 90.98 68.98 80.96
9 99.55 77.98 86.19
10 85.82 93.98
11 90.89 98.42
12 95.97 99.88
13 99.2 99.96
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Fig 7.20: In vitro release profiles of Nifedipine from the pulsatile release tablet
(PRT) coated    with different amount of HPMC E15LV.
           Fig 7.18 shows that HPMC K4M gives the lag time of 4 hours then follow the
sigmoidal release pattern with 100% drug release at 10th hour. As the concentration of
the HPMC K4 coating increases from 140 to 180 mg the lag time extended to 5 hours
and then follow the delayed release profile with the 100 % drug release at the 17th to 
18th hour  From  Fig  7.19,  it  was  observed  that  carboxymethylcellulose  sodium
(NaCMC) shows the lag time of 2 hours, resulting in rapid and complete drug release 
at 10th hour. But these tablet did not maintain its shape throughout dissolution process
which might be concluded that such tablet cannot be floated for longer period of the
time. Due to this reason tablet (PRT) of Carboxymethylcellulose sodium (NaCMC)
was not studied further.From fig 7.20 it was observed that HPMC E15LV shows the
lag time of 3 hours then follow the sigmoidal release pattern with 100% drug release
at 9th hour. As the concentration of the HPMC E15LV coating increases from 240 to
290 mg the lag time extended to 4.5 hours and then follow the delayed release profile
with the 100 % drug release at the 12th to 14th hour.From above discussion it was
cleared that carboxymethylcellulose sodium (NaCMC) cannot be used to develop a
successful pulsatile drug delivery system as it cannot give sufficient lag time and is
unable to maintain its shape. Other two polymers can be used to develop effective
pulsatile drug delivery system. But these two polymers were giving delayed release
pattern after sufficient lag time instead of giving pulsatile release pattern(complete
and rapid drug release at once).This may be due to the effect of superdisintegrants 
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(crosscarmellose sodium). Due to the insufficient swelling of crosscarmellose sodium,
it could not give burst release required for complete drug release. Hence these two
polymers were further studied by using KYRON T 314 as superdisintegrant in core
tablet. Different batches of pulsatile release tablet of HPMC K4M and HPMC E15LV
were prepared using KYRON T 314 in core tablet. Fig 7.21, 7.22 shows drug release
pattern of batches K1-K6. By studying dissolution profile it was observed that batch
K6(290mg)  was  optimized batch.  As the coated  tablet  was placed in  the  aqueous
medium, it was observed that the hydrophilic polymeric layer started erosion, which
underwent  progressive  modification  in  terms  of  thickness  and  consistency.  In  the
second phase of the dissolution procedure, the coating layer gradually starts to erode
up to a limiting thickness. After this stage, a rupture of the shell was observed under
the pressure applied by the swelling of the core tablet and Nifedipine released. This
pressure was high due to high swelling property of KYRON T314 and which resulted
in burst effect along with complete and rapid drug release. In case of other batches i.e 
K1, K2, K4 and K5 amount of coating polymer was too less to achieve desired lag
time.  Due  to  high  swelling  of  inner  core  tablet  coating  of  K1,  K2,  K4  and  K5
formulations could not maintain too long and result in complete drug release within
short  time.  All of  this process  corresponded to a  lag time capable of  exhibiting a
pulsatile release of the drug. The profiles relevant to the coated tablet showed that a
lag phase was followed by the quickly delivery of the active principle.  The delay
duration clearly depended on the kind and amount of hydrophilic polymer as which
was applied on the core. Invitro the lag time of the tablet coated with 290-mg HPMC
E15LV was 4.1±0.2 h and given burst with 96.88% and after this the % drug release
remains constant due to non maintenance of sink condition.
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Table 7.11: Dissolution Testing of batch K1-K3
Time (hrs.) % Drug Released
K1 K2 K3
0 0 0 0
1 0 0 0
2 20 0 0
3 27.98 5.98 0
4 51.54 15.9 5.98
5 65.89 29.87 30.98
6 77.97 45.76 50.39
7 83.78 53.21 67.29
8 90.98 68.98 80.96
9 99.55 77.98 86.19
10 85.82 93.98
11 90.89 98.42
12 95.97 99.88
13 99.2 99.96
Fig 7.21: In vitro release profiles of Nifedipine from the pulsatile release tablet
(PRT) coated with different amount of HPMC K4M+Core tablet containing
KYRON T 314.
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Table 7.12: Dissolution Testing of batch K4-K6
Time (hrs.) % Drug Released
K4 K5 K6
0 0 0 0
1 0 0 0
2 15.98 3.98 0
3 43.78 39.98 0
4 54.89 59.79 0
5 63.79 71.98 54.98
6 76.89 80.98 74.89
7 87.99 88.93 87.89
8 95.92 94.99 94.98
9 99.89 99.99 98.99
10 100.09 99.98
11 99.89 100.04
12 100.05 99.97
13 100.03 100.06
14 99.99 100.09
Fig 7.22: In vitro release profiles of Nifedipine from the pulsatile release tablet 
(PRT) coated with different amount of HPMC E15LV+Core tablet containing 
KYRON T 314 
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7.6.2 In Vitro Buoyancy Determination
Table no:13 Onset of time for floating of various formulations
Formulation Onset of time for floating
F1 Greater than 1 hr
F2 Formulation showed no floating
F3 Remaining floating was no more than 3 h
F4 float  completely  within  1  min  and
remained floating over a period of 12 h
F5 Greater than 15 min
       Floating behavior of tablet depends on added fillers in buoyant layer. Tablets
containing lactose floated earlier than tablets prepared with the inorganic filler dibasic
calcium  phosphate.  This  could  be  explained  by  the  different  densities,  lactose
containing  tablet  had  the  lowest  density  (1.0  g/cm3at  a  hardness  of  4.3  Kg/cm2),
whereas the dibasic calcium phosphate tablet had a much higher density (1.9 g/cm3 at
a hardness of 5.2 Kg/cm2 ). In addition, lactose has a higher water solubility, resulting
in faster water uptake of medium into tablet. Microcrystalline cellulose, an insoluble
filler with high water uptake and disintegration capability, resulted in disintegration of
tablet.CO2 did not  accumulate  in  buoyant  layer  of  tablet  and escaped  through the
disintegrated  tablet,  floating  was  therefore  not  achieved.  Based  on  these  results,
lactose was identified as the filler of choice and used for further investigation.
 F4 formulation was used for further investigation.
7.7 SWELLING INDEX DETERMINATION
         Tablet containing HPMC K4M showed high swelling index as compared to
HPMC E15LV and NaCMC which might be due to hydration property of HPMC
K4M.  NaCMC  showed  swelling  property  but  after  some  time  tablet  could  not
maintain its shape and integrity (Eq 6.1) HPMC K4M and HPMC E15LV  showed
constant increase in swelling index up to 10 h. (Fig 7.23)
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Fig 7.23: Swelling index of tablets of K3+F4, K6+F4 and C6
7.8 FLOATING AND PULSATILE RELEASE TABLET (FPRT)
       The FPRT was manufactured as described above and consisted of the buoyant
layer F4 (Table 6.8) combined with a PRT containing 20 mg Nifedipine core tablet
compression- coated with 290 mg of HPMC E15LV (Formulation K6). 
Table 7.14: Dissolution testing of batch K6+F4
Time (hrs.) % Drug Released
0 0
1 0
2 0
3 0
4 11.09
5 54.98
6 74.89
7 87.89
8 94.98
9 98.99
10 99.98
11 100.04
12 99.97
13 100.06
14 100.09
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Fig. 7.24: In vitro release profiles of Nifedipine from the floating–pulsatile
release tablet (FPRT) Of batch K6+F4
Evaluation Of Floating and Pulsatile Release Tablet:
         Only FPRT tablets of optimized batch (K6+F4) were evaluated for friability test,
hardness  test  and  drug  content.  In  formulation,  the  hardness  test  indicated  good
mechanical  strength.  Hardness  was ranged  from 3.8 to 4.0  Kg/cm2.  Friability was
ranged from 0.5 to 0.56. Friability is less than 1% which indicated that tablets had
good  mechanical  resistance.  Drug content  was  found to  be  high  (>99.23).  It  was
ranged  from 99.32 to  99.45 and uniform in all  tablet  formulations.  An ultraviolet
(UV) spectrophotometric method was  given at 236 nm and method obeys Beer's law
in concentration range 5 to 50 µg/ml, with good correlation coefficient (0.9997).
Table 7.15: Evaluation Of Floating and Pulsatile Release Tablet
Sr
no.
Formulations
Hardness
(Kg/cm2)
Friability (%)
Drug content
(%)
1 K6+ F4 3.8 0.43±0.11 99.45
7.10 STABILITY TESTING OF THE BEST FORMULATION
       According to the result of dissolution testing, the two batches were selected for
the stability studies K6+F4 out of the total formulation batches.Studies were carried
out as ICH guidelines
RESULTS OF STABILITY STUDIES FOR BATCH NO. K6+F4:
Sample at 30 C (+/-2 C) and 65% RH (+/-5%) condition
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Table no: 7.16: Results of stability studies for batch no. K6+F4.Sample at 30 C 
(+/-2)                              and 65% RH (+/-5%) condition
Tests Initial 7 days 14 days 21 days 1 month 2 month 3 month
Stability 
out date 2/10/11 9/10/11 16/10/11 23/10/11 30/10/11 30/11/11 30/12/11
Appearance white 
colour
white 
colour
white 
colour
white 
colour
white 
colour
white 
colour
white 
colour
LOD (%) 0.423 0.458 0.419 0.449 0.431 0.474 0.487
Assay (%) 99.73 99.65 99.57 98.48 99.33 99.26 99.14
Tests Initial 7 days 14 days 21 days 1 month 2 month 3 month
Stability
out date 2/10/11 9/10/11 16/10/11 23/10/11 30/10/11 30/11/11 30/12/11
Dissolution
study
Time (hr)
% Drug Release
0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0
2 0 0 0 0 0 0 0
3 0 0 0 0 0 0 0
4 5.24 7.54 5.89 4.66 4.36 7.32 5.89
5 13.86 14.24 12.54 11.35 14.38 12.54 13.33
6 33.67 48.3 37.78 37.37 58.3 34.06 37.38
7 54.73 55.52 48.96 57.36 65.52 52.32 57.32
8 69.99 76.28 65.55 65.29 76.28 68.53 65.27
9 87.77 92.92 76.98 77.26 92.92 89.70 77.26
10 96.35 98.59 86.42 85.24 98.59 95.93 96.44
11 98.25 96.96 98.79 98.76 96.96 99.80 98.76
12 99.38 99.18 99.88 100.66 99.18 100.19 100.07
13 98.99 100.89 99.86 99.41 100.89 100.54 99.50
14 98.35 98.57 98.98 98.57 98.57 99.78 98.56
15 99.57 99.67 100.39 98.99 99.67 98.44 98.98
Fig.7.25: LOD of stability batch K6+ F4, 300C±2 and 65% RH ±5% 
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Fig.7.26: % drug content of stability batch K6+F4, 300C±2 and 65% RH±5% 
Fig.7.27: Dissolution testing of stability batch K6+F4, Sample at 300C ±2  and
65% RH ±5%
Table no :17 Hardness, Friability,  Disintegration Time of batch        
                       K6+F4 at 300C±2 /65%RH ±5%
 
Days
Hardness
Kg/cm2
Friability
(%)
Disintegration
Time(S)
Initial 3.5 0.65±0.12 33
7 days 3.4 0.66±0.14 19
14 days 3.6 0.64±0.11 30
21 days 3.7 0.63±0.11 23
1 month 3.6 0.63±0.14 35
2 month 3.5 0.67±0.13 19
3 month 3.4 0.68±0.16 48
Table no: 7.18. Results of stability studies for batch no. K6+F4.Sample at 400C
(+/-2 C) and 75% RH (+/-5%) condition
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Tests Initial 7 days 14 days 21 days 1 month 2 month 3 month
Stability 
out date 2/10/11 9/10/11 16/10/11 23/10/11 30/10/11 30/11/11 30/12/11
Appearance white 
colour
white 
colour
white 
colour
white 
colour
white 
colour
white 
colour
white 
colour
LOD (%) 0.443 0.468 0.428 0.473 0.459 0.493 0.499
Assay (%) 99.11 99.23 100.17 98.28 99.56 99.72 99.86
Tests Initial 7 days 14 days 21 days 1 month 2 month 3 month
Stability
out date 2/10/11 9/10/11 16/10/11 23/10/11 30/10/11 30/11/11 30/12/11
Dissolution
study
Time (hr)
         
% Drug Release
0 0 0 0 0 0 0 0
1 0 0 0 0 0 0 0
2 0 0 0 0 0 0 0
3 0 0 0 0 0 0 0
4 5 2.37 5.12 4.56 3.46 2.14 1.03
5 13 4.36 9.43 7.32 7.54 5.89 4.66
6 33 14.38 25.86 12.54 14.24 12.54 11.35
7 54.73 58.3 34.06 34.06 48.3 37.78 37.37
8 69.99 65.52 52.32 52.32 55.52 48.96 57.36
9 87.77 76.28 68.53 68.53 76.28 65.55 65.29
10 96.35 92.92 89.70 89.70 92.92 76.98 77.26
11 98.25 98.59 95.93 95.93 98.59 86.42 85.24
12 99.38 96.96 99.80 99.80 96.96 98.79 98.76
13 98.99 99.18 100.19 100.19 99.18 99.88 100.66
14 98.35 100.89 100.54 100.54 100.89 99.86 99.41
15 99.57 98.57 99.78 99.78 98.57 98.98 98.57
Fig.7.28: LOD of stability batch K6+F4, Sample at 400C (+/-2 C) and 75% RH
(+/-5%)     
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Fig.7.29: % drug content of stability batch K6+F4, Sample at 400C (+/-2 C) and
75% RH (+/-5%) condition
Fig.7.30: Dissolution testing of stability batch K6+F4, Sample at 400C (+/-
2 C) and 75% RH (+/-5%) condition
            
Table no: 19 Hardness, Friability,  Disintegration Time(S) of batch
K6+F4 at 400C±2 /75%RH ±5%.
Days
Hardness
Kg/cm2
Friability
(%)
Disintegration
Time(S)
Initial
3.7
0.61±0.11
35
7 days 3.6 0.67±0.15 21
14 days 3.7 0.65±0.11 34
21 days 3.5 0.63±0.14 26
1 month 3.6 0.60±0.15 30
2 month 3.6 0.66±0.13 17
3 month 3.8 0.61±0.16 45
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       For Floating pulsatile release tablet of nifedipine optimized batch K6+F4 from
Table 7.12-7.13 , it was seen that there are no significant  changes in drug release
profile for the batches stored at 300C (+/-2 C) and 65% RH (+/-5%) and 400 C (+/-2
C) and 75% RH (+/-5%) when compared with initial batch.
From  the  stability  data  it  can  be  concluded  that  there  were  no  changes  in  any
parameter tested in formulation, so the optimized batch K6+F4 are said to be stable.
7.9 KINETICS OF DRUG RELEASE
Table No 7.20 Kinetics of Drug Release Study of K6+F4
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Batch
No
Zero
order
(R 2)
Firstorder
(R 2)
Higuchis
P lot (R 2)
Hxison
Crowell
(R 2)
Korsmeyer pepps
(R 2) (n) Order
release
K6+F4 0.7962 0.6541 0.9291 0.8355 0.9997 0.5854 Non -Fickian
                                                                                                                       Summary 
8. SUMMARY 
The main objective of the study was to develop a Time-Controlled release
formulation based on a Floating Pulsatile Drug Delivery System. The intention is that
the formulation should be administered in the evening at 22:00 in treating diseases in
which symptoms are experienced in the early morning hours (from 04:00 to 06:00).
The core tablets prepared with different superdisintegrants were subjected for
evaluation of the in-vitro disintegration time and it was observed that the time for
formulation varied from 10 to 52 second.  It will observed that when KYRON T314
was  used as disintegrant, tablet was disintegrate within short time due to easy and
high  swelling ability of  KYRON T314  as  compared  to  CCS.  It  is  observed  that
disintegration  time  of  tablet  decreased  with  increased  concentration  of  CCS  and
KYRON  T-314.  But  by  disintegration  study  it  was  observed  that  hardness  plays
important role. For development of pulsatile release study disintegration time must be
short to obtain burst effect therefore having less hardness. Hence by observing results
it was concluded that batches II and VI were optimized batches which was confirmed
by dissolution study.
Core tablet containing crosscarmellose sodium was compression-coated with
HPMC  K4,  HPMC  E15LV,  sodium  carboxymethylcellulose  (C1-C9)  and  these
batches were taken as preliminary batches for the study of individual polymers. 
HPMC K4M (Batch C1-C3) gives  the lag time of 4 hours then follow the
sigmoidal release pattern with 100% drug release at 10th hour. As the concentration of
the HPMC K4 coating increases from 140 to 180 mg the lag time extended to 5 hours
and then follow the delayed release profile with the 100 % drug release at the 17th to
18th hour. 
From dissolution study it was observed that carboxymethylcellulose sodium
(NaCMC) shows the lag time of 2 hours, resulting in rapid and complete drug release
at 10th hour (Batch C4-C6).  But these tablet did not maintain its shape throughout
dissolution process which might be concluded that such tablet cannot be floated for
longer period of the time. Due to this reason tablet (PRT) of Carboxymethylcellulose
sodium (NaCMC) was not studied further.
 HPMC E15LV (Batch C7-C9) shows the lag time of 3 hours then follow the
sigmoidal release pattern with 100% drug release at 9th hour. As the concentration of
the HPMC E15LV coating increases from 240 to 290 mg the lag time extended to 4.5
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hours and then follow the delayed release profile with the 100 % drug release at the
12th to 14th hour. 
Different  batches  of  pulsatile  release  tablet  of  HPMC  K4M  and  HPMC
E15LV were prepared using KYRON T 314 in core tablet (Batch K1-Batch K6). By
studying  dissolution profile  it  was observed  that  batch K6(290mg)  was  optimized
batch.
The behavior of the tablet is determined by using USP dissolution apparatus-II
in 500 ml of 0.1 N HCl.  Behavior  of tablet depends on added fillers (Dicalcium
phosphate,  microcrystalline cellulose and lactose) in buoyant layer.  F4 formulation
was found to float completely within 1 min and remained floating over a period of 12
h. The PRT was manufactured as described above and consisted of the buoyant layer
F4  (Table  4)  combined  with  a  PRT  containing  25  mg  Nifedipine  core  tablet
compression- coated with 290 mg of HPMC E15LV (Formulation K6). Lag time of
PRT coated with 290-mg HPMC E15LV was 4.1±0.2 h which was considered  as
suitable lag time for Nifedipine preventing the time-related occurrence of ischemic.
For  pulsatile release tablet of Nifedipine optimized batch  K6+F4 was selected for
stability testing,  it  was seen that  there are no significant   changes in drug release
profile for the batches stored at 300C (+/-2 C) and 65% RH (+/-5%) and 400 C (+/-2
C) and 75% RH (+/-5%) when compared with initial batch.Optimized batch K6+f4
was selected for kinetic study. The value of correlation coefficient is 0.9997 which
most near  to 1  and slope was found to be 0.584.Hence it  was concluded that  the
optimized batch was found to follw korsmeyer and peppas model.So it is concluded
that formulation release the drug by diffusion and erosion method.
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CONCLUSION
The core containing KYRON T-314  disintegrate the tablet within short
time due to easy and high swelling ability of KYRON T-314  as compared to
CCS The  PRT containing  the  buoyant  material,  such  as  HPMC  K100M,
NaHCO3,and citric acid achieved a satisfactory buoyant force in vitro, whereas
the floating onset time was less than 1 min. The pulsatile releasing mechanism
of  PRT  is  based  on  the  exploitation  of  the  peculiar  interaction  between
hydrophilic polymeric coating and the aqueous gastrointestinal fluids.
The in vitro release profiles of Nifedipine from PRT prepared using
HPMC E15LV as retarding polymer are characterized by a predetermined lag
time (4.1±0.2 h for K6+F4 ), the duration of which depends on the kind and
amount  of  the  polymeric  layer  applied  on  the  cores  as  well  as  type  of
superdisintegrant  in core tablet.  The developed system offers  a simple  and
novel technique for pulse release of drugs. From the results it is concluded that
the PRT we prepared could achieve a rapid release after lag time of 4±0.2h
with the relatively low variability. The drug release profile of optimized batch
K6+F4  was  found  to  be  follow korsmeyer  and  peppas  model.  So  it  is
concluded that formulation release the drug by diffusion and erosion method.
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